[{"text": "Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine \u00b7 Barrons.com Josh Nathan-Kazis Tue, Jan 21, 2025, 10:27 PM 3 min read In This Article: MRNA -7.28% The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat. Continue Reading View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-21T19:27:00+00:00", "sentiment": {"score": 0.04670172557234764, "confidence": 0.07235582172870636, "probabilities": {"positive": 0.07235582172870636, "negative": 0.02565409615635872, "neutral": 0.9019901156425476}}, "embedding": [0.0857260450720787, -0.12262982130050659, -0.10966923087835312, -0.021582018584012985, 0.03379690274596214, -0.04690873622894287, -0.01788901351392269, 0.06815767288208008, 0.03708827868103981, 0.2399289906024933, -0.03134200721979141, 0.019473407417535782, -0.03377952426671982, 0.06495967507362366, -0.29058489203453064, 0.11347627639770508, 0.08428826183080673, -0.09612203389406204, -0.08123207837343216, 0.14613886177539825, -0.2581137418746948, 0.18563656508922577, 0.2358013391494751, 0.07156839221715927, 0.06427314877510071, 0.04399438574910164, -0.2277766615152359, -0.028855111449956894, -0.006929540075361729, 0.03963480144739151, -0.03154825046658516, 0.0005614698748104274, -0.08496812731027603, -0.055428486317396164, -0.02485521137714386, -0.015848353505134583, 0.011305754072964191, 0.03258965164422989, 0.20367518067359924, 0.01644964888691902, 0.06990651041269302, -0.14437033236026764, 0.06346998363733292, -0.06514254212379456, 0.08835716545581818, 0.07482220232486725, -0.25083112716674805, 0.3108583986759186, 0.27626028656959534, 0.03315029293298721, -0.212998166680336, -0.316599041223526, 0.03989959508180618, 0.008452242240309715, -0.01483862567692995, 0.0907251387834549, -0.03817644342780113, -0.10762988030910492, -0.014818206429481506, 0.047929126769304276, -0.15070751309394836, -0.15117087960243225, 0.042275022715330124, 0.11762456595897675, 0.0598679780960083, -0.1377565562725067, -0.04844868183135986, 0.01163200568407774, 0.10261832177639008, 0.014114533551037312, 0.19683197140693665, -0.008584686554968357, -0.020638758316636086, -0.07096771895885468, 0.054274074733257294, 0.07503676414489746, 0.09973178803920746, 0.3040325343608856, 0.4093817174434662, -0.06927911192178726, 0.25719931721687317, -0.24833790957927704, 0.13687081634998322, -0.21879513561725616, 0.03447042778134346, 0.1543525606393814, 0.005273360293358564, -0.024257555603981018, 0.16648435592651367, -0.024912025779485703, -0.008422743529081345, -0.1846473515033722, 0.13925351202487946, 0.09371521323919296, -0.12384368479251862, 0.11604081094264984, -0.14896316826343536, -0.0024925428442656994, -0.15070833265781403, 0.07542015612125397, -0.07090415060520172, -0.11207981407642365, -0.027819672599434853, -0.24645362794399261, 0.059940047562122345, -0.10259753465652466, 0.002593321492895484, 0.025118904188275337, 0.06504791229963303, 0.15195846557617188, -0.1891092211008072, 0.1865696907043457, -0.06177536025643349, -0.038356296718120575, -0.10613588243722916, -0.04150799289345741, -0.02939715050160885, -0.2653631269931793, 0.13037842512130737, -0.1675017923116684, 0.10567576438188553, -0.09955660253763199, -0.14035598933696747, -0.14719490706920624, 0.0731462687253952, -0.13394193351268768, -0.25895822048187256, 4.161819014645093e-33, 0.07571206986904144, 0.013270891271531582, 0.24176757037639618, -0.027685506269335747, -0.1388334035873413, 0.015680143609642982, 0.01674254611134529, 0.1613631248474121, -0.11297544091939926, -0.23488940298557281, -0.24249425530433655, 0.048003025352954865, -0.03112146444618702, 0.23111553490161896, 0.02832920476794243, -0.17558224499225616, -0.018980320543050766, 0.08392737060785294, 0.10763657838106155, -0.015249566175043583, 0.135505810379982, 0.026765678077936172, 0.0929693728685379, 0.03257663920521736, 0.27562108635902405, 0.03177670016884804, -0.059511832892894745, 0.0050804330967366695, 0.0863136425614357, 0.04751833900809288, -0.18572679162025452, 0.10985267907381058, 0.08934760838747025, -0.2027910202741623, -0.013484806753695011, -0.08071469515562057, -0.02400083839893341, -0.20837068557739258, 0.01239862758666277, 0.24340292811393738, 0.06644870340824127, 0.086872398853302, -0.09262899309396744, 0.0505305714905262, 0.019383221864700317, 0.07135318219661713, -0.02408408559858799, 0.017314594238996506, -0.06548097729682922, 0.012698077596724033, 0.06757872551679611, 0.09655176103115082, -0.1867225021123886, -0.09483479708433151, -0.12005307525396347, -0.22155596315860748, -0.07079587131738663, -0.13587847352027893, 0.027670571580529213, -0.07434108108282089, -0.24143020808696747, -0.14173604547977448, 0.09815870970487595, 0.1130528375506401, -0.05620406195521355, 0.10455179214477539, 0.058416955173015594, 0.014465398155152798, -0.15445561707019806, 0.3136179447174072, 0.12562763690948486, -0.08671104907989502, -0.04902880638837814, -0.17348815500736237, -0.06105746701359749, -0.059140559285879135, 0.14096392691135406, 0.023200253024697304, 0.2480255663394928, 0.18301722407341003, -0.06104788929224014, 0.019993672147393227, 0.08494967222213745, 0.2565624713897705, 0.07322385162115097, 0.17414899170398712, 0.001532777096144855, 0.07131427526473999, 0.10124284029006958, -0.028016218915581703, 0.035850804299116135, 0.023147573694586754, -0.015026518143713474, 0.04468065872788429, 0.044392313808202744, -8.303886785460494e-33, -0.16938090324401855, 0.169451504945755, -0.15553852915763855, 0.2106270045042038, 0.01965777389705181, -0.02649569883942604, 0.015444542281329632, -0.0615650936961174, 0.1995920091867447, 0.03193150833249092, -0.19093762338161469, 0.020068466663360596, 0.15221333503723145, 0.029405632987618446, -0.06946665793657303, -0.05085771158337593, 0.04956795647740364, -0.08148925751447678, -0.005123949609696865, -0.03476376086473465, 0.10923420637845993, 0.1279943883419037, 0.10684233158826828, 0.012409198097884655, 0.014072559773921967, 0.03087357059121132, -0.04265297204256058, 0.1709485501050949, 0.02068566344678402, -0.17792727053165436, -0.11643768101930618, 0.010672397911548615, -0.1998680680990219, 0.09665851294994354, -0.2592115104198456, 0.23329012095928192, 0.2284736931324005, -0.10455457866191864, 0.19247403740882874, -0.21241068840026855, 0.21884265542030334, -0.047936707735061646, -0.23441241681575775, -0.033769167959690094, 0.08998239040374756, 0.02362256683409214, 0.06545186787843704, -0.04166865348815918, 0.06315993517637253, -0.022289307788014412, 0.0637868121266365, -0.14205090701580048, 0.006613536737859249, 0.11447007209062576, -0.21573017537593842, -0.028226541355252266, -0.023746328428387642, -0.17350058257579803, -0.012808137573301792, 0.09832602739334106, -0.07721688598394394, -0.0008415893535129726, -0.11692120134830475, -0.06749456375837326, 0.001498437370173633, 0.04985330253839493, 0.1547902673482895, 0.010098093189299107, 0.007946028374135494, -0.25560232996940613, 0.2561354339122772, 0.06919663399457932, -0.1377253383398056, 0.07452362030744553, -0.030837368220090866, 0.20361201465129852, 0.09977298974990845, 0.021972835063934326, 0.1221131682395935, 0.1891651302576065, 0.10140682011842728, -0.11903560906648636, 0.07876472920179367, -0.15273180603981018, 0.223901629447937, 0.009082971140742302, 0.17555829882621765, -0.2202996462583542, -0.13826097548007965, 0.19477207958698273, -0.305340439081192, -0.17271175980567932, 0.06949179619550705, -0.000867559458129108, -0.08375554531812668, -9.927855160185572e-08, 0.2471146136522293, -0.07062725722789764, -0.0634407326579094, -0.008809330873191357, 0.18503117561340332, -0.0454229936003685, -0.27161410450935364, 0.1633220911026001, 0.021261319518089294, 0.06133176013827324, 0.15011927485466003, 0.03325454145669937, -0.0035041370429098606, -0.009095342829823494, -0.11231816560029984, 0.09366457164287567, -0.34111806750297546, -0.04376242309808731, -0.15105149149894714, -0.12934675812721252, -0.05132578685879707, 0.2342766523361206, -0.09236804395914078, -0.06931792199611664, -0.04435897618532181, -0.00025272316997870803, 0.07062780112028122, 0.21354985237121582, -0.06651429831981659, -0.1408846080303192, -0.28340959548950195, -0.033558547496795654, -0.09534919261932373, 0.10081309825181961, -0.13648591935634613, -0.26164525747299194, 0.16592325270175934, 0.0020964841824024916, -0.01973523385822773, -0.021764766424894333, 0.0538598857820034, 0.009298562072217464, -0.14166344702243805, 0.023051155731081963, -0.3284927010536194, -0.0009452301310375333, -0.2862129211425781, -0.04861331731081009, 0.0919979140162468, -0.15761888027191162, 0.2404571920633316, 0.14058493077754974, 0.06554210931062698, 0.0007125820266082883, -0.05194041132926941, 0.025503939017653465, -0.039374370127916336, -0.13959543406963348, 0.0001602130214450881, -0.030306503176689148, -0.03138038143515587, -0.4319038689136505, 0.043587177991867065, 0.2318885326385498], "changes": {"1wk": -0.24374776691432365}}, {"text": "As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential Influenza A(H5N1) predominately affects wild birds and poultry. Credit: Pordee_Aomboon via Shutterstock. \u00b7 Clinical Trials Arena \u00b7 Pordee_Aomboon via Shutterstock. GlobalData Healthcare Tue, Jan 14, 2025, 5:42 PM 2 min read With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health officials are preparing for the potential of the virus adapting to enable human-to-human transmission. While there is no evidence yet that H5N1 could spread between humans, pandemic preparedness is essential, and messenger ribonucleic acid (mRNA) vaccines offer great potential to mitigate a future pandemic. Influenza A(H5N1) is classified as a highly pathogenic avian influenza virus that predominately affects wild birds and poultry. Since March 2024, there has been an ongoing, multistate outbreak among dairy cattle, affecting over 800 dairy herds across 16 states. Further, there were 66 confirmed cases of H5N1 influenza among humans in the US throughout 2024. Although H5N1 infections remain a low risk to the general public, they can cause severe disease and should be taken seriously. The first human H5N1 death was recorded in the US in January 2025. The US Centers for Disease Control and Prevention is carefully surveilling H5N1 outbreaks and exposures among humans, partnering with the US Department of the Interior, the US Department of Agriculture, and state and local health departments. This surveillance spans public health laboratories, emergency departments, clinical laboratory trends, and wastewater sources. Officials from the National Institute of Allergy and Infectious Diseases remain assured that the current outbreak can be controlled via collaboration, vigilant surveillance, the development of medical countermeasures, and prevention methods. This includes the development of a vaccine candidate, which could be swiftly manufactured and administered in the event of a widespread outbreak among humans. An mRNA H5N1 vaccine would be particularly beneficial in the event of a pandemic, as it can be manufactured much quicker than traditional vaccines. According to leading data and analytics company GlobalData , there are 12 vaccines in active clinical development (Phases I-III) indicated for pandemic influenza/influenza A(H5N1). Five of these vaccines are being manufactured utilising mRNA technology, including GSK/CureVac\u2019s influenza A/H5N1 vaccine, Moderna\u2019s mRNA-1018, and Sanofi\u2019s influenza H5 vaccine. The US Biomedical Advanced Research and Development Authority (BARDA), a department within the Administration for Strategic Preparedness and Response, is working to support pandemic influenza preparedness by partnering with developers and manufacturers, supporting the development of vaccines, diagnostics, and therapeutics, and funding ongoing clinical trials. Arcturus Therapeutics\u2019 H5N1 pandemic influenza vaccine candidate, ARCT-2304, is a self-amplifying mRNA vaccine candidate, whose Phase I clinical trial is funded by BARDA. The randomised, placebo-controlled, Phase I trial was initiated this week, and interim Phase I data is expected in the second half of 2025. Story Continues There are concerns surrounding the uncertainty of the H5N1 avian influenza virus; however, the implementation of pandemic preparedness measures, specifically the development of H5N1 mRNA vaccines, offers great potential to mitigate a future pandemic. \"As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-14T14:42:27+00:00", "sentiment": {"score": 0.13612131401896477, "confidence": 0.15550316870212555, "probabilities": {"positive": 0.15550316870212555, "negative": 0.019381854683160782, "neutral": 0.8251149654388428}}, "embedding": [-0.04183941334486008, -0.1347215324640274, 0.05399162694811821, -0.022327721118927002, 0.09171362966299057, 0.06695230305194855, -0.0499575212597847, 0.042309440672397614, 0.0013798451982438564, 0.15915466845035553, -0.043919339776039124, 0.12719234824180603, -0.07312682271003723, 0.08701206743717194, -0.12585382163524628, 0.017158418893814087, -0.03103509731590748, -0.16429372131824493, -0.12821698188781738, 0.03660164773464203, 0.02563195303082466, 0.169586181640625, 0.01642204448580742, 0.0978582501411438, -0.13701575994491577, -0.1704830676317215, -0.06630204617977142, 0.11511118710041046, -0.21782046556472778, -0.029527291655540466, 0.013960592448711395, -0.07454736530780792, 0.05987706407904625, 0.024229027330875397, -0.14564082026481628, -0.029070638120174408, 0.070046067237854, -0.13645972311496735, 0.13859190046787262, 0.006408031098544598, 0.04437856003642082, -0.02968565560877323, 0.07931766659021378, -0.013965689577162266, 0.16863220930099487, 0.10326660424470901, -0.1305115669965744, 0.09132340550422668, 0.0639917403459549, 0.029391571879386902, -0.09258054196834564, -0.11777234077453613, 0.14399701356887817, 0.008509675040841103, 0.04717935994267464, -0.09391075372695923, -0.18171824514865875, -0.10421561449766159, -0.03667398542165756, -0.029204757884144783, -0.17725124955177307, -0.10687218606472015, 0.07850220799446106, -0.030362538993358612, 0.06878691911697388, 0.011302033439278603, 0.0009936587885022163, -0.008957283571362495, 0.09523415565490723, 0.1139000952243805, 0.006168918684124947, 0.0002410421147942543, -0.06261903792619705, 0.06851822137832642, -0.035529881715774536, 0.22783708572387695, 0.13135682046413422, 0.05755670368671417, 0.34406206011772156, -0.1345539689064026, 0.08623315393924713, -0.011192581616342068, 0.25366878509521484, -0.0027386685833334923, -0.13370823860168457, 0.0014768564142286777, 0.07424459606409073, 0.1234876811504364, -0.03626617416739464, -0.06893682479858398, -0.0008113465737551451, -0.1286124885082245, 0.1427624523639679, 0.0388806089758873, 0.008964203298091888, 0.0002520461566746235, -0.029834028333425522, 0.10314519703388214, 0.011566254310309887, 0.057424381375312805, -0.06085588037967682, -0.2295531928539276, -0.0015901951119303703, -0.02216319367289543, -0.029378816485404968, 0.0857742577791214, -0.01980755291879177, -0.021219972521066666, 0.07068894803524017, 0.049553871154785156, -0.24748319387435913, 0.2022751420736313, -0.08318741619586945, -0.09640543162822723, 0.04578206315636635, 0.11643557250499725, -0.031083974987268448, -0.21141618490219116, -0.010452879592776299, -0.1750386357307434, 0.10671540349721909, -0.1483391672372818, 0.07069887220859528, -0.01912553980946541, 0.1256389319896698, 0.06472804397344589, -0.0789797231554985, 1.1032199622827423e-32, 0.10727190971374512, -0.1683412790298462, 0.22498616576194763, 0.13664551079273224, 0.013955878093838692, -0.007958652451634407, -0.0610128790140152, 0.02425818145275116, 0.06323301792144775, -0.09640724211931229, -0.0552578866481781, -0.05266889929771423, 0.032274819910526276, 0.11218574643135071, -0.005435931961983442, -0.05594051629304886, 0.0707305520772934, 0.014070207253098488, -0.0825362354516983, 0.0606633722782135, 0.041120290756225586, -0.07775764167308807, -0.028304744511842728, 0.07040749490261078, 0.04732643812894821, 0.09190157055854797, -0.077892005443573, -0.07652712613344193, 0.09470106661319733, -0.008442502468824387, -0.1009691059589386, -0.07406377047300339, -0.07781803607940674, -0.002035839483141899, -0.007988499477505684, -0.16028855741024017, -0.0297181848436594, -0.018867865204811096, 0.03416888043284416, 0.12335240840911865, 0.19920942187309265, 0.06096552684903145, 0.008341830223798752, 0.03275018930435181, 0.22938261926174164, 0.005238668527454138, -0.20407512784004211, 0.04738478362560272, -0.21234846115112305, -0.013407568447291851, 0.11190739274024963, -0.038748741149902344, 0.03005516715347767, -0.16260409355163574, -0.025555476546287537, -0.06455714255571365, -0.05889288708567619, -0.11056201905012131, 0.05353941768407822, 0.09784834831953049, -0.020940586924552917, 0.028838003054261208, 0.0106285335496068, 0.01548122987151146, 0.0003113057464361191, -0.007153757847845554, 0.09755457937717438, -0.056772757321596146, 0.0216642078012228, 0.2566893696784973, 0.09548742324113846, -0.037094272673130035, -0.08241594582796097, -0.14818868041038513, -0.054853618144989014, 0.049673791974782944, 0.06086274981498718, -0.008545570075511932, 0.027278874069452286, 0.12590157985687256, -0.14129950106143951, -0.042131517082452774, 0.04748348891735077, 0.0859718918800354, -0.15532717108726501, -0.11180956661701202, 0.035550203174352646, -0.08618903160095215, 0.016596876084804535, -0.00487086595967412, 0.08377432078123093, 0.12278488278388977, 0.09774290025234222, 0.013222454115748405, 0.08265841007232666, -1.1665963728653413e-32, -0.13974037766456604, -0.004254024941474199, -0.16860441863536835, 0.047273408621549606, -0.22131839394569397, 0.08671040087938309, 0.12604999542236328, -0.06388872861862183, 0.06442613154649734, -0.20250356197357178, -0.05173906683921814, -0.0736892968416214, 0.07748851180076599, -0.07338272035121918, -0.0406031608581543, 0.06509760767221451, -0.02106374502182007, 0.011909855529665947, -0.07835572957992554, 0.031212370842695236, -0.06511667370796204, 0.05885913223028183, -0.049226365983486176, 0.0019785920158028603, 0.07851054519414902, 0.15342062711715698, -0.007482461631298065, 0.19815891981124878, 0.14756673574447632, -0.12374237924814224, -0.1116953045129776, 0.02182202786207199, 0.002358078956604004, -0.003364508505910635, -0.09785187244415283, 0.03984244167804718, 0.24386796355247498, -0.11233080923557281, 0.003720687935128808, -0.1623823642730713, 0.04085845127701759, 0.042544886469841, -0.04248460382223129, 0.06767064332962036, -0.11158037930727005, 0.18348637223243713, -0.00032867491245269775, 0.03410583734512329, 0.026237551122903824, -0.0009597539901733398, 0.0563257597386837, -0.0667787715792656, -0.0034619863145053387, -0.03494423255324364, -0.15365470945835114, -0.07430952787399292, 0.01567457802593708, -0.15440762042999268, -0.0612342394888401, 0.12295764684677124, 0.04647736996412277, -0.010912579484283924, -0.05691730976104736, 0.023669729009270668, 0.07640020549297333, -0.05641493201255798, 0.07162389159202576, -0.039610907435417175, 0.03402547165751457, -0.3082025349140167, 0.03425472974777222, 0.0736597403883934, 0.033666133880615234, -0.02680719830095768, 0.059355396777391434, 0.026981418952345848, 0.040727581828832626, -0.01689419522881508, 0.03538797050714493, 0.12985676527023315, -0.10472119599580765, -0.0800970047712326, -0.09951643645763397, -0.025969624519348145, 0.11940035969018936, -0.11823810636997223, 0.1672070026397705, 0.09104177355766296, 0.12648960947990417, 0.06254315376281738, -0.1545896828174591, 0.011647626757621765, -0.08481721580028534, 0.004979133140295744, -0.18326790630817413, -9.99992550987372e-08, 0.2011014074087143, -0.06278230249881744, 0.07110311090946198, -0.0476207509636879, 0.05022713541984558, 0.11713742464780807, -0.19320504367351532, 0.06448575854301453, 0.2057635486125946, 0.2326088547706604, 0.05567343905568123, 0.2000197470188141, -0.04556974023580551, -0.08444540202617645, 0.013144353404641151, -0.02845902368426323, -0.16833683848381042, -0.027959540486335754, -0.12001975625753403, 0.02456769533455372, -0.1610122174024582, 0.04007740318775177, -0.21144667267799377, -0.1380869746208191, 0.11707614362239838, -0.21296842396259308, 0.030366914346814156, 0.05480821430683136, 0.0630643293261528, -0.18141858279705048, -0.22101497650146484, -0.03663618117570877, 0.005324878729879856, -0.06226160004734993, -0.06082195043563843, -0.01085636019706726, 0.16399356722831726, 0.027233995497226715, 0.06444069743156433, 0.04035848006606102, 0.03773229569196701, -0.0446859672665596, -0.029673442244529724, -0.1012394055724144, -0.04126999154686928, -0.13295325636863708, -0.008594771847128868, 0.0036148633807897568, 0.04493546485900879, -0.13677769899368286, -0.10604952275753021, 0.008143998682498932, 0.13325276970863342, 0.00017471611499786377, -0.12584039568901062, 0.02343497797846794, -0.009188234806060791, -0.1751786172389984, 0.24353066086769104, 0.011289030313491821, 0.04997103288769722, -0.1504022777080536, -0.009693410247564316, 0.19466514885425568], "changes": {"1wk": -1.0849927879458325}}, {"text": "Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial Business Wire Fri, Jan 10, 2025, 4:00 PM 6 min read In This Article: ARCT -6.89% LUNAR-H5N1 becomes the third STARR\u00ae mRNA vaccine candidate to enter clinic First Phase 1 participant injected December 2024 Interim Phase 1 data expected H2 2025 SAN DIEGO, January 10, 2025 --( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the \"Company\", \"Arcturus\", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company\u2019s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The randomized placebo-controlled Phase 1 trial ( NCT06602531 ) is being conducted at multiple sites in the U.S. and designed to enroll approximately 200 healthy adults (120 participants 18-59 years old; 80 participants 60-80 years old). Screening of study participants began November 2024, with the first participant inoculated in December 2024. The clinical study is fully funded by Biomedical Advanced Research and Development Authority (BARDA). The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune responses are measured by hemagglutination inhibition (HAI), virus microneutralization (MN) and neuraminidase enzyme-linked lectin assays (ELLA). ARCT-2304 (LUNAR-H5N1) utilizes clinically validated LUNAR\u00ae delivery and STARR\u00ae mRNA platform technologies. STARR\u00ae mRNA has demonstrated in multiple clinical trials its ability to elicit a robust immune response at very low dose levels, with extended persistence of neutralizing antibodies compared to approved conventional mRNA vaccines. The robust safety database of the LUNAR and STARR technologies have been established through multiple COVID-19 and seasonal influenza vaccine trials, which included more than 20,000 participants and dose ranges from 1 to 20 mcg of mRNA. \"Clinically validating our low-dose STARR\u00ae mRNA technology in H5N1 flu is a crucial step towards pandemic preparedness,\" said Joseph Payne, President and CEO of Arcturus Therapeutics. \"Our team is working diligently with our partners, BARDA and CSL, in the United States and globally in this effort.\" About H5N1 Influenza H5N1 influenza is a significant concern in animal health. To date, H5N1 flu has affected over 10,000 wild birds, nearly a thousand dairy cows, and over 130 million poultry. Elevated H5N1 infections in animals have led to increasing numbers of human infections including two confirmed severe cases in the United States and one death. Most of the confirmed 67 human infections are due to exposure of U.S. dairy and poultry workers to infected dairy cows and poultry. Story Continues About sa-mRNA mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike conventional mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response. About ARCT-2304 (LUNAR-H5N1) ARCT-2304, also known as LUNAR-H5N1, is a sa-mRNA vaccine candidate formulated with Arcturus proprietary LUNAR\u00ae delivery technology. The sa-mRNA vaccine candidate is designed to make many copies of mRNA within the host cell after intramuscular injection to achieve enhanced expression of haemagglutinin (HA) and neuraminidase (NA) antigens, thereby enabling lower doses than conventional mRNA vaccines. Utilizing a mRNA-based platform for pandemic influenza vaccine development offers further options for meeting domestic vaccine manufacturing surge capacity goals. The technology may make vaccines available much sooner than egg- and cell-based technologies. The lyophilized vaccine formulation is stable in refrigerators, thereby simplifying cold-chain storage and reducing distribution risks. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE\u00ae, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com . In addition, please connect with us on Twitter and LinkedIn . Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding the likelihood of success (including safety and efficacy) of ARCT-2304, the timing for the interim Phase 1 data, the targeted enrollment and continued conduct of the Phase 1 study of ARCT-2304, the likelihood that preclinical or clinical results received to date will be predictive of future results (including with respect to the safety data generated to date), the continued involvement and support of BARDA and collaboration with CSL, the likelihood of success of the Company\u2019s development and related efforts for an influenza vaccine candidate, the future activities under and fulfillment of the Company\u2019s contract with BARDA, the ability of the Company\u2019s influenza vaccine technologies to support U.S. government pandemic preparedness goals, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading \"Risk Factors\" in Arcturus\u2019 most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC\u2019s website at www.sec.gov . Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. View source version on businesswire.com: https://www.businesswire.com/news/home/20250110432449/en/ Contacts Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-10T13:00:00+00:00", "sentiment": {"score": 0.18782840948551893, "confidence": 0.1967296600341797, "probabilities": {"positive": 0.1967296600341797, "negative": 0.008901250548660755, "neutral": 0.7943690419197083}}, "embedding": [-0.06289493292570114, -0.17123785614967346, 0.03980407118797302, -0.06850840151309967, 0.037377696484327316, -0.00986374169588089, -0.08070651441812515, 0.23124316334724426, -0.04047293961048126, 0.07688282430171967, -0.10619381070137024, 0.0831093043088913, 0.03434671834111214, 0.016127193346619606, -0.0955972969532013, 0.07248685508966446, 0.14861206710338593, -0.07083002477884293, -0.1251169890165329, -0.06608586758375168, 0.02362632192671299, 0.03440520912408829, 0.008948294445872307, 0.07251572608947754, -0.0877051055431366, -0.07826785743236542, -0.14597772061824799, -0.024586942046880722, -0.19117549061775208, -0.08381998538970947, 0.06662064790725708, 0.005644489079713821, -0.06644057482481003, 0.02010771818459034, -0.17004147171974182, -0.10328221321105957, -0.03213360905647278, -0.10035640001296997, 0.029471151530742645, -0.012383837252855301, 0.014299417845904827, 0.013947629369795322, -0.03371754288673401, -0.07348434627056122, 0.246254101395607, -0.024604199454188347, -0.07154922932386398, -0.04162587225437164, 0.08939577639102936, 0.2650526762008667, 0.008149927482008934, -0.07143628597259521, -0.024221904575824738, 0.07843702286481857, -0.06837904453277588, -0.07651962339878082, -0.15095332264900208, 0.014449961483478546, 0.06975266337394714, 0.057165250182151794, -0.16686080396175385, -0.13832680881023407, -0.0026883333921432495, -0.023883389309048653, 0.04514237865805626, 0.04737015441060066, -0.07602740824222565, -0.024849379435181618, 0.07192980498075485, -0.023997562006115913, -0.02385522797703743, 0.06107096001505852, -0.1278822273015976, 0.26315659284591675, -0.011271916329860687, 0.20387232303619385, 0.21340474486351013, 0.10649344325065613, 0.24714873731136322, -0.10155177116394043, 0.05052902176976204, 0.12800027430057526, 0.2323758900165558, 0.1405254304409027, -0.04882333055138588, 0.09533152729272842, 0.017873689532279968, 0.24229955673217773, 0.014582062140107155, -0.022570230066776276, 0.14925584197044373, -0.02120920643210411, -0.023381976410746574, 0.08891642838716507, -0.0579942911863327, -0.012787532061338425, -0.045437585562467575, 0.04142371565103531, -0.014963286928832531, 0.09369969367980957, -0.04792376980185509, -0.0807945728302002, -0.01450339239090681, -0.1347145438194275, -0.06294798105955124, -0.0069404486566782, 0.04735133796930313, -0.18933528661727905, 0.05074313282966614, 0.03211083263158798, -0.0923713743686676, 0.03205445781350136, 0.0033287815749645233, -0.07477208971977234, 0.0396784245967865, 0.17232529819011688, -0.18690577149391174, -0.06940135359764099, 0.12352122366428375, -0.11301995813846588, 0.1316252052783966, -0.15217779576778412, 0.11366771161556244, -0.10930898785591125, 0.022432245314121246, 0.0339055061340332, 0.022444987669587135, 1.256070815151309e-32, 0.045152705162763596, 0.025649480521678925, 0.06997130811214447, 0.11436033993959427, -0.08436986804008484, -0.07260493189096451, -0.016382090747356415, 0.1697516143321991, -0.07182561606168747, -0.11827047169208527, -0.11098310351371765, -0.05423827841877937, -0.018613016232848167, 0.10828888416290283, -0.07801324129104614, 0.008004172705113888, 0.04302186891436577, -0.0658796951174736, -0.14299023151397705, -0.019950546324253082, 0.06792362034320831, -0.07610157132148743, -0.06997741758823395, -0.04271398484706879, 0.05256723612546921, 0.07388809323310852, -0.01760215312242508, 0.05252613127231598, -0.007557947188615799, 0.023916330188512802, -0.14846214652061462, 0.006623893044888973, 0.04885932058095932, -0.0418119840323925, -0.042239632457494736, -0.06165715679526329, -0.10947830975055695, -0.07120239734649658, 0.002258048392832279, 0.08248154073953629, 0.20913410186767578, 0.14623115956783295, -0.08600306510925293, 0.04676970839500427, 0.18789304792881012, -0.10829329490661621, -0.1923866868019104, -0.028111804276704788, -0.08213171362876892, -0.011877740733325481, 0.04522968456149101, 0.046546149998903275, 0.07245302200317383, -0.1020665392279625, 0.053529880940914154, 0.05655870959162712, -0.07834294438362122, -0.060061268508434296, 0.08937865495681763, 0.07423631846904755, 0.033612437546253204, -0.05345270410180092, -0.005328204948455095, 0.08069613575935364, -0.09378674626350403, 0.144813671708107, 0.023640720173716545, -0.1369665563106537, -0.04707008972764015, 0.03295881301164627, 0.08005138486623764, -0.08735977113246918, 0.035873401910066605, -0.08880709111690521, -0.05264958366751671, -0.0755431205034256, 0.22645899653434753, 0.09366568177938461, -0.010867081582546234, 0.03402118384838104, -0.1031382828950882, -0.044492900371551514, -0.011881322599947453, 0.13436314463615417, -0.047879524528980255, -0.07829543948173523, 0.05931737646460533, -0.04036206752061844, -0.18058380484580994, -0.020503303036093712, 0.23931410908699036, 0.0653378888964653, 0.10993005335330963, 0.13492903113365173, 0.021231384947896004, -1.0874177917246383e-32, -0.14447146654129028, -0.025535032153129578, -0.1905589997768402, -0.030399702489376068, -0.10960771888494492, 0.17098519206047058, 0.2378372848033905, -0.09586796164512634, 0.11307457089424133, -0.028126608580350876, 0.054797444492578506, -0.07760165631771088, 0.00941998977214098, -0.09489458799362183, 0.0430181547999382, 0.030463628470897675, -0.0412476509809494, 0.05709916353225708, -0.07684467732906342, 0.1685548722743988, 0.058921921998262405, 0.20176714658737183, -0.017383098602294922, -0.037767406553030014, 0.04217807203531265, 0.030146732926368713, 0.10062640905380249, 0.08606976270675659, 0.12831804156303406, -0.052861474454402924, -0.07999448478221893, 0.08720982074737549, -0.06962870806455612, 0.10162882506847382, -0.0768933817744255, -0.0034784041345119476, 0.24394536018371582, -0.1387457698583603, -0.09177658706903458, -0.1522502601146698, 0.03183216229081154, 0.10136011242866516, -0.10871021449565887, -0.01733296550810337, -0.024358466267585754, 0.21078623831272125, 0.06558628380298615, 0.040290869772434235, 0.09064988046884537, 0.11017099767923355, 0.02122560143470764, -0.15381476283073425, -0.00047038355842232704, 0.04193974658846855, -0.11719110608100891, -0.09586086869239807, 0.035474397242069244, -0.06686344742774963, -0.11817796528339386, 0.05638131871819496, -0.07210315018892288, -0.07138876616954803, -0.047124989330768585, -0.029267452657222748, 0.04003247618675232, 0.12132468074560165, 0.12165964394807816, 0.06339659541845322, 0.009354066103696823, -0.17212191224098206, 0.015422232449054718, -0.03031846322119236, 0.13174761831760406, -0.15652069449424744, -0.011208039708435535, 0.021402422338724136, 0.012570954859256744, -0.0007530373986810446, -0.1036912351846695, 0.0320635624229908, -0.16223789751529694, 0.008722720667719841, -0.11405835300683975, 0.02220413275063038, 0.13683933019638062, -0.06409836560487747, 0.011666642501950264, 0.020909275859594345, 0.015234249643981457, 0.12325029820203781, -0.048701025545597076, -0.05412285774946213, -0.053132668137550354, 0.036154940724372864, -0.04861774295568466, -1.0017156171215902e-07, 0.217973530292511, -0.05058051645755768, -0.04190904274582863, 0.04429095983505249, -0.043827883899211884, 0.01783696934580803, -0.13304351270198822, 0.02659345418214798, -0.024210289120674133, 0.12408924847841263, 0.11292140185832977, 0.14873819053173065, -0.1269945502281189, -0.13309408724308014, 0.0423140749335289, 0.05647799000144005, -0.10051202774047852, 0.05708862096071243, -0.09459078311920166, 0.030639346688985825, -0.01561065949499607, 0.035059474408626556, -0.01968155987560749, -0.08271747082471848, 0.0705782026052475, -0.08667509257793427, 0.07049861550331116, 0.07086476683616638, 0.023014606907963753, -0.2338084876537323, -0.21697403490543365, 0.012542473152279854, -0.025823727250099182, -0.11841756105422974, -0.162177175283432, -0.023778919130563736, 0.20018216967582703, 0.15810923278331757, 0.12457508593797684, 0.14061635732650757, 0.04704579710960388, 0.018839405849575996, -0.037902720272541046, -0.09819218516349792, -0.033114537596702576, -0.059318866580724716, 0.04282250255346298, -0.06017600744962692, 0.07748661190271378, -0.1721237748861313, -0.11992381513118744, 0.012760336510837078, 0.08549394458532333, -0.13852843642234802, -0.14335796236991882, 0.15576346218585968, -0.06126239150762558, -0.12698398530483246, 0.11138768494129181, -0.013428610749542713, 0.0005352683365345001, -0.1513187736272812, 0.03279688209295273, 0.00401783362030983], "changes": {"1wk": -5.394879521970472}}, {"text": "Arcturus Therapeutics launches Phase I Avian Influenza trials in US The AI system allows for the quantitative characterisation of solid lung nodules and enables clinicians to analyse morphological data across single or multiple thoracic studies. Credit: Shutterstock / New Africa. \u00b7 Clinical Trials Arena Joshua Silverwood Fri, Jan 10, 2025, 7:14 PM 2 min read In This Article: ARCT -6.89% GLDAF +4.44% California vaccine company Arcturus Therapeutics has announced the launch of a Phase I trial of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate designed to combat the H5N1 virus, known as bird flu, days after the US announced its first fatality. The company\u2019s vaccine candidate, also known as LUNAR-H5N1, will be examined in a randomised placebo-controlled trial (NCT06602531) in 200 healthy adults with the first participant having already been inoculated in December of last year. The trial's primary endpoints are safety and immune response across three different dose levels. Trial funding has come from the US Biomedical Advanced Research and Development Authority (BARDA). The announcement follows shortly after the US Centres for Disease Control (CDC) confirmed the first US death from H5N1 at a Louisiana hospital. At the time of publication, the CDC knows of 66 confirmed human cases of H5N1 bird flu in the United States since 2024 and 67 since 2022. Joseph Payne, CEO of Arcturus Therapeutics, said: \u201cClinically validating our low-dose STARR mRNA technology in H5N1 flu is a crucial step towards pandemic preparedness.\u201d As part of the trial, participants will be randomised to receive either two doses of the ARCT-2304 vaccine or one dose of another licensed influenza vaccine alongside a single dose of placebo. The first phase of the trial will examine the vaccine in 120 adults between the ages of 18 and 59, before moving on to test the vaccine in the remaining 80 participants aged between 60 and 80. Otherwise known as bird flu or avian influenza, H5N1 is a zoonotic disease, meaning that under the right circumstances, it has the ability to be transmitted to humans, often through repeated and consistent contact. In the veterinary world, vets and researchers have been combatting waves of bird flu, thought to originate in eastern Europe and Russia, since 2021. Research by GlobalData currently estimates the general global market for avian influenza vaccines to be worth approximately $25m by the end of 2030. GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the influenza market, FluGen has published the results of a Phase I trial showing that its intranasal flu vaccine, M2SR, increases in efficacy when used in when used in combination with Sanofi\u2019s Fluzone high dose. Meanwhile, Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, CC-4234. \"Arcturus Therapeutics launches Phase I Avian Influenza trials in US\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. Story Continues The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-10T16:14:13+00:00", "sentiment": {"score": 0.12517274171113968, "confidence": 0.13721245527267456, "probabilities": {"positive": 0.13721245527267456, "negative": 0.012039713561534882, "neutral": 0.8507477641105652}}, "embedding": [0.02423863299190998, -0.05517534539103508, 0.02058006078004837, -0.020603083074092865, 0.06618162989616394, -0.045136164873838425, -0.017730263993144035, 0.16330140829086304, 0.035024430602788925, 0.1825064718723297, -0.08185477554798126, 0.09883059561252594, 0.01706218719482422, 0.04951479658484459, -0.15356123447418213, 0.01314980536699295, 0.07351674139499664, -0.17314329743385315, -0.1184205710887909, 0.044161438941955566, -0.07126156985759735, 0.11414943635463715, 0.08965281397104263, 0.07399626821279526, -0.14698709547519684, -0.12489403039216995, -0.170728862285614, -0.023277942091226578, -0.17460238933563232, -0.0441056564450264, 0.1333228051662445, 0.013316351920366287, -0.09980735927820206, 0.03266856446862221, -0.12087340652942657, -0.10073520243167877, 0.016434242948889732, -0.0957198366522789, 0.09194640070199966, 0.025864634662866592, 0.045945458114147186, -0.03771074116230011, 0.029504552483558655, 0.004431977868080139, 0.21815812587738037, 0.007757617626339197, -0.17237751185894012, 0.06763003021478653, 0.12116578221321106, 0.1584765464067459, -0.06446274369955063, -0.13888302445411682, -0.035030849277973175, 0.09827477484941483, -0.08862262964248657, -0.08180541545152664, -0.14490169286727905, -0.037387602031230927, 0.0029524308629333973, -0.007284063845872879, -0.1363554298877716, -0.1056523397564888, -0.051083728671073914, 0.005479410290718079, 0.08935623615980148, 0.01852904073894024, -0.03766816109418869, -0.11023534834384918, 0.15003708004951477, 0.10287383198738098, 0.06133921444416046, 0.0031668152660131454, -0.13717123866081238, 0.17301331460475922, -0.025871962308883667, 0.19306379556655884, 0.14587032794952393, 0.06096780300140381, 0.2786402106285095, -0.11058121919631958, 0.15211693942546844, 0.02446560561656952, 0.23500651121139526, -0.008431555703282356, -0.038007572293281555, -0.013684181496500969, 0.006697165779769421, 0.17412680387496948, 0.014428413473069668, -0.09920710325241089, 0.06029438599944115, -0.06634494662284851, 0.07413378357887268, 0.0812705010175705, 0.009557375684380531, 0.01250450313091278, -0.005949311889708042, 0.06280981749296188, 0.019396789371967316, 0.11628756672143936, -0.08028136193752289, -0.252727210521698, 0.02078724466264248, -0.028424642980098724, -0.05344538763165474, 0.043173011392354965, -0.03430212289094925, -0.1766369789838791, 0.03927836939692497, -0.012357761152088642, -0.20178987085819244, 0.12567919492721558, -0.010531565174460411, -0.0007396945729851723, 0.03645407408475876, 0.13692903518676758, -0.1332998275756836, -0.10863020271062851, 0.05003642290830612, -0.10215982794761658, 0.11391948163509369, -0.1927051544189453, 0.026545681059360504, -0.13613855838775635, 0.08054696768522263, 0.04220700263977051, -0.12952443957328796, 1.1517411364752215e-32, 0.09558740258216858, -0.06236832216382027, 0.14124056696891785, 0.13120757043361664, -0.04513576626777649, -0.020806672051548958, -0.09070183336734772, 0.048563987016677856, -0.036021992564201355, -0.11093500256538391, -0.1525275707244873, -0.05878223851323128, -0.020729433745145798, 0.020579509437084198, -0.038084764033555984, 0.018423305824398994, -0.03505142778158188, 0.06475311517715454, -0.14927464723587036, 0.004804455675184727, 0.04624243453145027, -0.028040923178195953, -0.07669150084257126, -0.04428049921989441, 0.08431102335453033, 0.08997368812561035, -0.1581888645887375, -0.024542905390262604, 0.07133509963750839, 0.02265082485973835, -0.10737717896699905, 0.049891166388988495, 0.004860932007431984, 0.017665132880210876, -0.014150438830256462, -0.06864020228385925, -0.05073987692594528, -0.06879507005214691, 0.009848070330917835, 0.131944939494133, 0.20775361359119415, 0.10405848920345306, -0.06402236223220825, 0.0670962780714035, 0.17687439918518066, -0.14144597947597504, -0.2021198868751526, -0.028995517641305923, -0.15424185991287231, 0.050990596413612366, 0.05363374575972557, 0.025677945464849472, 0.04741242900490761, -0.166385680437088, 0.025390706956386566, 0.06535904109477997, -0.02940102107822895, -0.08950991928577423, 0.07459860295057297, 0.06074375659227371, 0.05265642702579498, -0.033806491643190384, 0.007217706646770239, 0.028174225240945816, -0.03747596964240074, 0.05178767070174217, 0.07907745987176895, -0.13370288908481598, -0.03767302632331848, 0.06538811326026917, 0.10085039585828781, -0.060489412397146225, -0.025838123634457588, -0.16555853188037872, -0.031083151698112488, -0.08529285341501236, 0.17620694637298584, 0.15540891885757446, 0.038614511489868164, -0.0030434532091021538, -0.06409267336130142, -0.022572997957468033, 0.016147075220942497, 0.17264209687709808, -0.11707620322704315, -0.025149069726467133, 0.04223283380270004, -0.04203827679157257, -0.12644897401332855, -0.05827871710062027, 0.1973131000995636, 0.11987979710102081, 0.1166946142911911, 0.015500950627028942, 0.05017179250717163, -1.1486031543057014e-32, -0.2130054235458374, -0.07432424277067184, -0.19830790162086487, 0.059145063161849976, -0.054571330547332764, 0.16472724080085754, 0.17527374625205994, -0.07684001326560974, 0.0866008847951889, -0.05798669531941414, 0.009200303815305233, -0.03418472781777382, 0.09626390039920807, -0.03619328886270523, -0.04605335742235184, 0.004965460859239101, -0.0020524829160422087, 0.01358732208609581, -0.036181796342134476, 0.09922861307859421, 0.06926093995571136, 0.0823805034160614, -0.025862637907266617, -0.054611265659332275, 0.01276073232293129, 0.0562838539481163, 0.09111081063747406, 0.057499129325151443, 0.11760026216506958, -0.1368664801120758, -0.11761358380317688, 0.09029284864664078, -0.07128044217824936, 0.059615690261125565, -0.014023970812559128, 0.04940449818968773, 0.2636938691139221, -0.048266902565956116, -0.08423502743244171, -0.215793177485466, 0.025409787893295288, 0.10908280313014984, -0.09458987414836884, -0.0376698262989521, 0.011175621300935745, 0.15727737545967102, 0.157424658536911, 0.06130378693342209, 0.025524519383907318, 0.01445414312183857, 0.023286497220396996, -0.10346993803977966, -0.03645072877407074, 0.00753804249688983, -0.13263235986232758, -0.06214851886034012, 0.0017515439540147781, -0.12788735330104828, -0.08647967129945755, 0.07364724576473236, -0.06423585116863251, -0.01570083200931549, -0.10609033703804016, 0.003282750491052866, 0.08459059149026871, 0.06032754108309746, 0.02366270124912262, 0.03988635912537575, -0.009170936420559883, -0.14434531331062317, -0.027765564620494843, -0.0008056121878325939, 0.00685371458530426, -0.09564824402332306, 0.05497300624847412, 0.062374964356422424, 0.04554123058915138, -0.10440561175346375, -0.024091210216283798, 0.03562292829155922, -0.15687662363052368, -0.03684374690055847, -0.064338818192482, -0.04350140690803528, 0.09710069745779037, -0.08798271417617798, 0.07411788403987885, -0.023211516439914703, 0.027629006654024124, 0.09690549969673157, -0.09593741595745087, -0.025846734642982483, -0.0762518048286438, -0.01300029642879963, -0.09495749324560165, -1.0043346776456019e-07, 0.24247956275939941, 0.04526735842227936, 0.0428939051926136, 0.06553538143634796, 0.03111792728304863, 0.015770323574543, -0.12344823032617569, 0.026126105338335037, 0.05854806303977966, 0.1532873511314392, 0.018116086721420288, 0.1266447901725769, 0.04369375482201576, -0.12763410806655884, 0.023063603788614273, 0.07343527674674988, -0.074383445084095, 0.0643521249294281, -0.1439468264579773, 0.04396964609622955, -0.06852030754089355, 0.08431035280227661, 0.0556398369371891, -0.13639366626739502, 0.10711967200040817, -0.07743030786514282, 0.06485612690448761, 0.06577694416046143, -0.017203830182552338, -0.17954909801483154, -0.2815290093421936, 0.0027308259159326553, -0.12218265235424042, -0.04695488139986992, -0.12250933051109314, -0.09926530718803406, 0.1762780249118805, 0.10248585790395737, 0.08904673904180527, 0.0049381256103515625, 0.032016728073358536, 0.020676836371421814, -0.03819681704044342, -0.03674548864364624, 0.030790293589234352, -0.036154936999082565, 0.004521187394857407, -0.09119830280542374, 0.07657354325056076, -0.13914670050144196, -0.057503871619701385, 0.029134277254343033, 0.0836334228515625, -0.14070093631744385, -0.07182528078556061, 0.16352760791778564, 0.00292214285582304, -0.12659914791584015, 0.13484998047351837, -0.0398821160197258, 0.05809132009744644, -0.13674475252628326, 0.007341496646404266, 0.10116995871067047], "changes": {"1wk": -6.618457491690092}}, {"text": "PREMIUM Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies MT Newswires Tue, Jan 7, 2025, 12:26 AM 1 min read In This Article: ARCT -6.89% Arcturus Therapeutics (ARCT) said Monday it started dosing patients with cystic fibrosis and ornithi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-06T21:26:12+00:00", "sentiment": {"score": 0.04901334922760725, "confidence": 0.06086944043636322, "probabilities": {"positive": 0.06086944043636322, "negative": 0.01185609120875597, "neutral": 0.9272744655609131}}, "embedding": [-0.010349418967962265, -0.06282663345336914, 0.07734125852584839, 0.08905205875635147, 0.004902460612356663, -0.011858728714287281, -0.014126232825219631, 0.30197980999946594, -0.08260585367679596, -0.034177523106336594, 0.059865448623895645, 0.08803573250770569, 0.08023691177368164, 0.09038566052913666, 0.012331709265708923, 0.06622359156608582, 0.22617578506469727, -0.06844247132539749, 0.01744266040623188, 0.027349859476089478, -0.016653094440698624, 0.09069067984819412, 0.10998250544071198, 0.02144540287554264, -0.010089821182191372, -0.023562133312225342, -0.016407392919063568, -0.07168445736169815, -0.037175502628088, 0.012757194228470325, -0.11411122232675552, 0.008352215401828289, -0.0021462172735482454, -0.08637718111276627, 0.024464014917612076, -0.1870889812707901, -0.01649414375424385, -0.01559093501418829, 0.016768470406532288, 0.0595325268805027, 0.10270553827285767, -0.13377295434474945, -0.15775033831596375, 0.14115343987941742, 0.01019993331283331, -0.15448340773582458, -0.12175628542900085, -0.09955079853534698, 0.08469560742378235, 0.1570705771446228, -0.04924555867910385, -0.13869048655033112, 0.13930277526378632, 0.01950698345899582, -0.024759691208600998, -0.031953077763319016, -0.10473829507827759, 0.008179454132914543, -0.09460265934467316, 0.009265008382499218, -0.05077415332198143, -0.049877457320690155, -0.14085188508033752, 0.10082882642745972, 0.029862718656659126, 0.06775429099798203, 0.10431677103042603, 0.02752869948744774, 0.02543589100241661, -0.004723171703517437, -0.004971482791006565, 0.005473090335726738, -0.06456434726715088, 0.35050728917121887, 0.10917827486991882, 0.10332413762807846, 0.1879405528306961, -0.013886647298932076, 0.05484818294644356, -0.0820142850279808, 0.038164254277944565, 0.045017506927251816, 0.1160164400935173, 0.05847356468439102, 0.011347642168402672, -0.06839855760335922, 0.10213106870651245, 0.17854323983192444, 0.05640387535095215, -0.12536396086215973, 0.18460704386234283, 0.08111417293548584, 0.042251475155353546, -0.04167713597416878, -0.051283132284879684, 0.010972286574542522, -0.07492177933454514, -0.07826852053403854, -0.10820814222097397, -0.034834105521440506, -0.053740859031677246, -0.08267813920974731, 0.017792103812098503, -0.027654539793729782, -0.11360891908407211, -0.01053617987781763, 0.048412345349788666, 0.002449329011142254, 0.07208286970853806, -0.024116527289152145, -0.026528259739279747, -0.0879814475774765, 0.1605040282011032, -0.0833296999335289, -0.06977163255214691, 0.26209425926208496, -0.0980645939707756, 0.07139499485492706, 0.14946304261684418, 0.06566069275140762, 0.08608977496623993, -0.05282597988843918, -0.024284133687615395, 0.07985661178827286, -0.05183987319469452, 0.11811444163322449, -0.14804819226264954, 1.6114974012961637e-32, -0.0420895479619503, 0.09340186417102814, -0.05571529269218445, 0.036518365144729614, -0.005167773924767971, 0.07922821491956711, 0.03502288833260536, -0.10312764346599579, -0.014355163089931011, -0.191804438829422, -0.027236947789788246, 0.012704937718808651, -0.04932206869125366, 0.05058839172124863, -0.2310316562652588, -0.252257764339447, -0.00369540904648602, 0.06598291546106339, 0.031659144908189774, 0.06817459315061569, 0.057242050766944885, 0.0013829980744048953, -0.08593955636024475, -0.07779622077941895, -0.10119380056858063, 0.10954093188047409, 0.06251758337020874, 0.0420195572078228, 0.1301255077123642, 0.03960159048438072, 0.039329592138528824, -0.02458113804459572, -0.021882308647036552, -0.12851084768772125, -0.03509725257754326, -0.025288844481110573, 0.050131138414144516, -0.03141370043158531, 0.01931474171578884, -0.08417922258377075, -0.098868727684021, 0.034390997141599655, -0.12081887573003769, 0.06414168328046799, 0.07545448839664459, -0.1663392186164856, -0.14919519424438477, 0.049685124307870865, 0.014158600941300392, -0.06506045162677765, -0.015268689952790737, 0.051431916654109955, -0.14467553794384003, 0.005979964043945074, -0.0005674267886206508, 0.00283541576936841, -0.11839122325181961, -0.1593177765607834, 0.10994257032871246, -0.1138807013630867, 0.2751607894897461, -0.016920197755098343, 0.05152500048279762, -0.07042242586612701, -0.18011581897735596, 0.01718084327876568, -0.1629560887813568, -0.22478792071342468, -0.21925294399261475, 0.1464737057685852, 0.015936393290758133, 0.0017299996688961983, 0.0341419018805027, 0.008760560303926468, -0.022496946156024933, -0.09061278402805328, 0.01606091670691967, 0.11142703145742416, -0.01928863301873207, -0.06818720698356628, -0.040144167840480804, -0.1554977297782898, 0.12353216111660004, 0.11018099635839462, 0.1249019205570221, 0.03553617373108864, -0.07281408458948135, 0.12379717826843262, -0.13891077041625977, -0.003924378659576178, 0.21854130923748016, 0.054205525666475296, -0.12338446080684662, 0.1803845316171646, 0.050752028822898865, -1.5563495246377177e-32, -0.08317159116268158, 0.0837201401591301, -0.12686631083488464, -0.06347835808992386, -0.021189726889133453, 0.04334826394915581, -0.017594968900084496, 0.12327557057142258, 0.21224579215049744, -0.04420628026127815, 0.06127624213695526, 0.031198594719171524, -0.14173780381679535, -0.11164180189371109, 0.057550519704818726, 0.11605160683393478, -0.00962194986641407, -0.049824006855487823, -0.11773452162742615, 0.046406008303165436, -0.09869671612977982, 0.039069291204214096, -0.09454984962940216, 0.12607938051223755, 0.07642919570207596, 0.048749346286058426, 0.009618420153856277, 0.09453059732913971, -0.002143255667760968, 0.11815762519836426, -0.014266302809119225, 0.008187209255993366, -0.13647015392780304, -0.03175808861851692, -0.028462324291467667, 0.019243914633989334, 0.18051666021347046, -0.09162717312574387, -0.13349251449108124, -0.03215521201491356, 0.04521357640624046, -0.049618590623140335, -0.09375100582838058, -0.009144969284534454, 0.013441123068332672, 0.05307256430387497, 0.16975176334381104, -0.14187081158161163, 0.06322598457336426, 0.011018067598342896, 0.025948693975806236, -0.055780671536922455, 0.16625109314918518, 0.021221155300736427, -0.09201748669147491, 0.029818635433912277, 0.07886166870594025, -0.08274278044700623, -0.02670655958354473, -0.06465597450733185, 0.013307363726198673, 0.10644493252038956, -0.13368536531925201, -0.10077719390392303, -0.004880016203969717, 0.23714737594127655, 0.00013358845899347216, 0.03576343506574631, 0.04989422485232353, -0.01819581724703312, -0.15574854612350464, -0.15205171704292297, -0.10341672599315643, -0.1920071691274643, -0.06628324091434479, 0.1907474547624588, -0.028892304748296738, -0.06783643364906311, -0.1289656013250351, 0.02850567176938057, 0.010957983322441578, -0.020261546596884727, -0.05062044784426689, -0.04431449621915817, -0.06110336259007454, -0.1072256788611412, -0.003933274652808905, 0.04472479596734047, -0.12864407896995544, 0.12883739173412323, -0.10285022109746933, -0.15671023726463318, -0.09360501915216446, 0.21173492074012756, 0.20819291472434998, -1.0086445456636284e-07, 0.02387038804590702, -0.04391850531101227, -0.0006849264027550817, 0.07850152999162674, 0.03281771019101143, -0.06535503268241882, -0.12306641042232513, 0.060044895857572556, -0.06193222105503082, 0.08852597326040268, -0.11156227439641953, 0.12981262803077698, -0.01736922562122345, 0.07462949305772781, 0.12952037155628204, 0.09181617200374603, 0.07648924738168716, 0.16132737696170807, -0.04863440617918968, -0.08645769208669662, -0.1383945196866989, -0.07086589932441711, 0.12021786719560623, -0.07373037189245224, -0.07298112660646439, 0.037265531718730927, 0.0723683163523674, 0.12995360791683197, 0.049720268696546555, -0.1321902871131897, -0.10369165241718292, 0.03628278523683548, -0.17485103011131287, 0.0036472317297011614, -0.1321835070848465, 0.03450300917029381, -0.08146543800830841, -0.011460775509476662, 0.09168845415115356, 0.07470191270112991, -0.014917710795998573, 0.02567582204937935, 0.08195289969444275, 0.1169445738196373, 0.08015891164541245, -0.026472285389900208, -0.030606452375650406, -0.21414496004581451, 0.09855936467647552, -0.16010381281375885, 0.03179120272397995, -0.09043975174427032, 0.10845791548490524, -0.05102028697729111, -0.10557243973016739, 0.15366514027118683, -0.044727813452482224, -0.041862525045871735, -0.1251843422651291, 0.003624066710472107, -0.049813393503427505, -0.11086829006671906, 0.22147443890571594, -0.024189138785004616], "changes": {"1wk": -9.229157089916036}}, {"text": "Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Business Wire Tue, Jan 7, 2025, 12:01 AM 8 min read In This Article: ARCT -6.89% First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024 Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025 SAN DIEGO, January 06, 2025 --( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the \"Company\", \"Arcturus\", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company\u2019s Phase 2 multiple ascending dose studies. Each participant in the Phase 2 CF study ( NCT06747858 ) is expected to receive daily treatments of ARCT-032 over a period of 28 days. The first OTC deficient participant receiving 0.5 mg/kg ARCT-810 initiated dosing in December 2024 in the United States. Each participant is expected to receive five intravenous infusions administered over two months. The Company previously announced the completion of the dosing phase (N = 8; 0.3 mg/kg) in a placebo-controlled European study enrolling OTC deficient individuals and expansion of the Phase 2 clinical program of ARCT-810 into the United States with an open-label multiple-dose study ( NCT06488313 ). \"We are very pleased with the recent progress in our Phase 2 studies in people with cystic fibrosis and OTC deficiency. ARCT-032 has the potential to address the significant unmet medical need in the CF community for those who do not qualify for or benefit from available treatment options,\" said Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics. \"ARCT-810 is the only mRNA therapy currently in clinical development intended to enable liver cells to produce OTC enzyme and therefore address the underlying cause of OTC deficiency.\" About Cystic Fibrosis Cystic fibrosis is a life-shortening disease with a worldwide prevalence. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in a reduction or absence of CFTR protein and/or function in the airways, causing disruption of ion transport necessary to maintain airway surface homeostasis. CF mucus is more difficult to clear, thus clogging the airways and leading to infection, inflammation, and progressive lung damage that may ultimately result in respiratory failure. Standard of care for many CF individuals include CFTR modulators. Nearly 40,000 people in the U.S. and more than 105,000 people worldwide are living with CF. Approximately 15% of individuals with CF do not benefit from CFTR modulator medicines due to absent CFTR protein and/or drug intolerance. Story Continues About ARCT-032 ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with CF. ARCT-032 has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) and Orphan Drug Designation along with Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) to treat cystic fibrosis. ARCT-032 utilizes Arcturus\u2019 LUNAR \u00ae lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. Lung disease is the leading cause of morbidity and mortality in people with CF. Expression of a functional copy of the CFTR mRNA in the lungs of people with CF has the potential to restore CFTR activity and mitigate the downstream effects that cause progressive lung disease. The ARCT-032 program is supported by preclinical data in rodents, ferrets and primates, as well as the demonstration of restoration of CFTR expression and function ex-vivo in human bronchial epithelial cells. About Ornithine Transcarbamylase Deficiency Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder. Urea cycle disorders are a group of inherited metabolic disorders that make it difficult for affected patients to remove toxic waste products as proteins are digested. OTC deficiency is caused by mutations in the OTC gene which leads to a non-functional or deficient OTC enzyme. OTC is a critical liver enzyme which catalyzes an early step in the urea cycle, a metabolic process that converts ammonia to urea. This conversion does not occur properly in patients with OTC deficiency. A deficiency of the OTC enzyme in liver cells can result in high blood ammonia levels and may cause seizures, progressive neurocognitive impairment, coma, and death in untreated patients. OTC deficiency is an inherited X-linked disorder that usually presents early in life, but patients with less severe symptoms may present later in life, as adults. There is currently no cure for OTC deficiency, apart from liver transplant. However, this treatment comes with significant risk of complications such as organ rejection, and transplant recipients must take immunosuppressant drugs for the rest of their lives. The current standard of care for OTC deficiency patients is a well-controlled, but challenging to maintain, low-protein diet and treatment with nitrogen scavenging medications to try to prevent patients from accumulating ammonia. These treatments do not address the underlying cause of disease. In Europe and the U.S., approximately 10,000 people have OTC deficiency. About ARCT-810 ARCT-810 is an intravenously administered investigational mRNA therapeutic designed to express normal functional OTC enzyme in the liver of individuals with OTC deficiency. ARCT-810 has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA), including an approved pediatric investigation plan (PIP), and Orphan Drug Designation along with Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ornithine transcarbamylase deficiency. OTC is a key enzyme in the urea cycle which converts toxic ammonia into urea. Elevated ammonia can lead to metabolic crises with progressive and irreversible neurocognitive damage. A safe and effective mRNA therapeutic may restore normal functional OTC enzyme in the liver which could eliminate the risk of future metabolic crises. ARCT-810 is based on Arcturus\u2019 mRNA design construct and proprietary manufacturing process. ARCT-810 also utilizes Arcturus\u2019 extensive and propriety lipid library and employs the Company's LUNAR\u00ae delivery platform to deliver OTC mRNA to hepatocytes. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE\u00ae, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com . In addition, please connect with us on Twitter and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success (including safety and efficacy) of ARCT-810 or ARCT-032, the timing for interim data for both studies, the expected treatment regimens and periods in the studies, the potential for ARCT-032 to benefit null patients or other CF patients, the continued clinical development of ARCT-032 and ARCT-810, the likelihood that preclinical or clinical results received to date will be predictive of future clinical results, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading \"Risk Factors\" in Arcturus\u2019 most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC\u2019s website at www.sec.gov . Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. View source version on businesswire.com: https://www.businesswire.com/news/home/20250106386740/en/ Contacts Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-06T21:01:00+00:00", "sentiment": {"score": 0.41157627385109663, "confidence": 0.4206004738807678, "probabilities": {"positive": 0.4206004738807678, "negative": 0.009024200029671192, "neutral": 0.5703753232955933}}, "embedding": [-0.027111783623695374, -0.12511485815048218, 0.035888925194740295, -0.003527206601575017, -0.09542766213417053, -0.04919140040874481, -0.03690420836210251, 0.3824871778488159, 0.03679674118757248, -0.0028036371804773808, -0.0051026372238993645, 0.04905347898602486, 0.08052099496126175, 0.08809775859117508, -0.04449556767940521, 0.0541347935795784, 0.10602177679538727, -0.02432786300778389, -0.022286757826805115, 0.01119061280041933, 0.016887523233890533, 0.02364812232553959, 0.10453018546104431, 0.02631295844912529, -0.07832924276590347, -0.07422176748514175, -0.03193921595811844, -0.060148973017930984, -0.15615133941173553, -0.023996030911803246, -0.07961368560791016, 0.1530226171016693, -0.0008011488243937492, -0.027133438736200333, -0.009478572756052017, -0.10638533532619476, -0.012128068134188652, -0.02497318759560585, 0.00559840677306056, 0.02672259509563446, 0.0220956951379776, -0.005850653164088726, -0.061587557196617126, 0.0628543421626091, 0.0893247127532959, -0.1705019474029541, -0.07499609887599945, -0.06245312839746475, 0.006881900131702423, 0.23083971440792084, 0.03479702025651932, -0.028659339994192123, 0.013098270632326603, 0.07357194274663925, -0.0757831409573555, 0.03256083279848099, -0.09296900033950806, 0.06174403429031372, -0.043668560683727264, 0.08423562347888947, -0.056997254490852356, -0.10604141652584076, -0.0424509234726429, -0.0007211077027022839, 0.17184752225875854, 0.034349262714385986, 0.11331477761268616, -0.028648516163229942, 0.03717435896396637, -0.06279119104146957, -0.0010989666916429996, -0.0456683412194252, -0.17387887835502625, 0.28390032052993774, 0.022352946922183037, 0.09999839961528778, 0.19247892498970032, 0.06367631256580353, 0.06395804136991501, -0.0697852224111557, 0.04070144519209862, 0.08727280795574188, 0.09725623577833176, -0.013460805639624596, -0.047849688678979874, -0.017415408045053482, 0.024771198630332947, 0.26290011405944824, 0.05012776330113411, -0.014108054339885712, 0.1290975958108902, 0.04127604514360428, 0.026836471632122993, 0.004579856060445309, 0.0023437682539224625, -0.003242889419198036, -0.01048626285046339, 0.11227250099182129, -0.015041694045066833, -0.013339366763830185, 0.029732301831245422, -0.1132112592458725, -0.030219826847314835, -0.05214790254831314, -0.03456994146108627, -0.034722182899713516, 0.08364728093147278, -0.11442030966281891, -0.014367761090397835, -0.053984638303518295, -0.06079605966806412, -0.03954606503248215, 0.14169789850711823, -0.07438989728689194, -0.010992771945893764, 0.20757019519805908, -0.023134462535381317, 0.05211431533098221, 0.15457914769649506, 0.09735063463449478, 0.10545622557401657, -0.07286340743303299, 0.08840881288051605, -0.04141595959663391, -0.03144729509949684, 0.05260540544986725, -0.03981327638030052, 1.387234238057586e-32, -0.04392553120851517, 0.014576898887753487, -0.04863441735506058, 0.1584072858095169, -0.036738209426403046, 0.022606519982218742, 0.03637220710515976, -0.027765704318881035, -0.07791289687156677, -0.12962044775485992, -0.06437809020280838, 0.005289848893880844, -0.018570322543382645, 0.002280673012137413, -0.17417648434638977, -0.1420007199048996, 0.06184585392475128, 0.0007543540559709072, -0.05450748652219772, -0.005721662659198046, 0.0031202053651213646, -0.02076197788119316, 0.02024637907743454, -0.03724239021539688, -0.005442543886601925, 0.11520032584667206, -0.049380090087652206, 0.06040892004966736, 0.04686807468533516, -0.021572571247816086, -0.0026637697592377663, 0.016570458188652992, 0.026916634291410446, -0.058874569833278656, -0.0208908561617136, -0.11475183814764023, 0.03470723330974579, -0.07432155311107635, 0.06852631270885468, 0.0605459064245224, -0.021353021264076233, 0.05980725586414337, -8.626992348581553e-05, -0.012894587591290474, 0.13767360150814056, -0.172110915184021, -0.1761699616909027, 0.056489236652851105, -0.06450291723012924, -0.05871721729636192, 0.06586651504039764, -0.02673444151878357, -0.06648240238428116, -0.0889439731836319, 0.08839040994644165, -0.033908411860466, -0.20533433556556702, -0.13549473881721497, 0.0702308639883995, 0.11423592269420624, 0.15404772758483887, 0.06556251645088196, -0.049684494733810425, 0.07979783415794373, -0.11085503548383713, 0.04982922226190567, -0.06459216773509979, -0.18724170327186584, -0.14262905716896057, 0.06742522865533829, -0.00750992214307189, -0.11484827846288681, 0.09053140133619308, 0.04802047461271286, 0.12120454013347626, -0.10905879735946655, 0.1796180158853531, 0.11517542600631714, -0.05547604709863663, -0.07145823538303375, -0.09518426656723022, -0.07582056522369385, 0.008016407489776611, 0.1607324630022049, 0.056980282068252563, -0.06607663631439209, -0.022393740713596344, 0.0005814187461510301, -0.2006162405014038, -0.013425312004983425, 0.19442318379878998, 0.04750068858265877, -0.0909762978553772, 0.1430111974477768, 0.0792541354894638, -1.2634790744237788e-32, -0.04851667210459709, 0.02584824711084366, -0.18693727254867554, -0.17032063007354736, -0.0349724218249321, 0.1329105645418167, 0.16721409559249878, -0.10028166323900223, 0.11806973814964294, -0.14462584257125854, 0.03357509896159172, -0.022286051884293556, -0.07515352964401245, -0.09931926429271698, -0.041129808872938156, 0.036231063306331635, -0.04873036593198776, 0.03146621584892273, -0.12373235821723938, 0.07720239460468292, 0.008548783138394356, 0.03373028337955475, -0.05709034204483032, -0.02197221666574478, 0.04448039084672928, 0.0341264046728611, 0.024767082184553146, 0.07211892306804657, 0.03435972332954407, 0.03169150650501251, -0.07264368236064911, 0.028987977653741837, -0.10487638413906097, 0.03422414883971214, -0.023446377366781235, 0.029668351635336876, 0.13258402049541473, -0.15966327488422394, -0.10522372275590897, -0.09097188711166382, -0.006266063079237938, 0.08882373571395874, -0.16896048188209534, -0.07786384224891663, -0.03529369831085205, 0.05415291339159012, 0.16027520596981049, -0.15515875816345215, 0.08687140047550201, 0.0048278518952429295, 0.06692969799041748, -0.0673985630273819, 0.08394742757081985, 0.025949012488126755, -0.05002313852310181, 0.03015071153640747, 0.06899023056030273, -0.080706387758255, 0.06257987022399902, -0.014211327768862247, 0.023433690890669823, 0.02400418370962143, 0.02128846012055874, -0.09059913456439972, 0.049193721264600754, 0.16641771793365479, -0.010354714468121529, 0.08918498456478119, 0.03987367823719978, -0.04989715665578842, -0.1026345044374466, -0.13299013674259186, 0.0066554956138134, -0.19929605722427368, -0.017993545159697533, 0.11696617305278778, -0.09759216755628586, -0.06888669729232788, -0.10092596709728241, -0.05855393037199974, -0.1318724900484085, 0.009250989183783531, -0.051863621920347214, 0.0920758843421936, 0.024947866797447205, -0.09992069751024246, 0.029795758426189423, 0.014013818465173244, 0.037422820925712585, 0.13542765378952026, -0.028345664963126183, -0.14326827228069305, -0.03138189762830734, 0.16728442907333374, 0.0667160302400589, -1.0092372804137995e-07, 0.09451809525489807, 0.010939495638012886, -0.07466442883014679, -0.04263570159673691, 0.02948552928864956, 0.003045402467250824, -0.12807440757751465, -0.0007300097495317459, -0.057886525988578796, 0.12592238187789917, 0.014959588646888733, 0.2220730036497116, -0.04677726700901985, 0.010244103148579597, 0.07130645960569382, 0.17511437833309174, -0.03923336789011955, 0.08636902272701263, -0.06880839169025421, -0.029499676078557968, -0.13160130381584167, 0.016751468181610107, -0.0031563322991132736, -0.0009169140830636024, -0.002547803334891796, -0.048960503190755844, 0.06742829829454422, 0.2220403254032135, 0.05472157895565033, -0.11697986721992493, -0.06695306301116943, -0.05144611746072769, -0.08766891807317734, -0.02403213642537594, -0.14820951223373413, -0.10688061267137527, -0.0021638888865709305, 0.051701419055461884, 0.013042902573943138, 0.15722650289535522, -0.07908950746059418, 0.011464137583971024, -0.006299784407019615, 0.0927954837679863, 0.14991497993469238, -0.10262446105480194, -0.07689733058214188, -0.08950799703598022, 0.01752614416182041, -0.1457335352897644, -0.03696826845407486, 0.03180275484919548, 0.00726549606770277, -0.07525520771741867, -0.03269839286804199, 0.119183748960495, -0.019702520221471786, -0.037623319774866104, -0.08694036304950714, -0.07652769982814789, -0.14541083574295044, -0.005321188364177942, 0.1711065173149109, -0.08792074024677277], "changes": {"1wk": -9.229157089916036}}, {"text": "Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization Demand Muslim Farooque Tue, Jan 7, 2025, 7:26 PM 1 min read In This Article: MRNA -7.28% NVAX -2.99% PFE -1.21% Tuesday saw bumps in Moderna ( NASDAQ:MRNA ), Novavax ( NASDAQ:NVAX ), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing. Moderna rose 11%; Novavax and others, including Inovio Pharmaceuticals (INO), CureVac ( NASDAQ:CVAC ), and Arcturus Therapeutics ( NASDAQ:ARCT ), also traded significantly higher. Manufacturers of the COVID-19 vaccination Comirnaty, Pfizer ( NYSE:PFE ) and BioNTech ( NASDAQ:BNTX ), noted more meager increases. Warning! GuruFocus has detected 6 Warning Signs with MRNA. Based on last week's U.S. Centers for Disease Control and Prevention (CDC) data showing increasing COVID-19 activity in most areas and a concurrent rise in seasonal flu, especially among small children, the rally followed last week's Citing their success in lowering serious disease and hospitalization, the CDC advised Americans to get recommended vaccinations. The organization also underlined how common respiratory syncytial virus (RSV) is in young children. With its mREVIA medicine, Moderna has joined Pfizer's Abysvo and GSK's Arexvy vaccines on the RSV vaccination market. As health authorities stress preventative actions, the increasing need for vaccinations to treat certain respiratory diseases has attracted investment attention in the sector. This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2025-01-07T16:26:33+00:00", "sentiment": {"score": 0.8982969522476196, "confidence": 0.9304265975952148, "probabilities": {"positive": 0.9304265975952148, "negative": 0.032129645347595215, "neutral": 0.03744374215602875}}, "embedding": [-0.016092097386717796, -0.1408098191022873, -0.1006879210472107, -0.00534200482070446, 0.09877132624387741, 0.09554531425237656, 0.039278678596019745, 0.20242083072662354, 0.015859484672546387, 0.12151144444942474, -0.0230012945830822, 0.07407733052968979, 0.104698546230793, 0.15367554128170013, -0.002848866395652294, 0.035867467522621155, 0.060552582144737244, -0.07830741256475449, -0.09220230579376221, 0.01625807210803032, -0.049293890595436096, 0.09065097570419312, 0.1607581377029419, 0.027616633102297783, -0.06256049126386642, 0.011688949540257454, -0.14936107397079468, -0.022152572870254517, -0.07420007884502411, -0.06450670957565308, -0.00044450783752836287, 0.05661303550004959, 0.030529120936989784, -0.060170695185661316, -0.06182165816426277, -0.0525992326438427, -0.0023243315517902374, 0.08064375817775726, 0.008461312390863895, -0.008648360148072243, 0.029075857251882553, 0.021984776481986046, -0.09433292597532272, -0.03539200872182846, 0.044616907835006714, -0.0469900406897068, -0.13289138674736023, 0.06764861196279526, 0.14607763290405273, 0.06667051464319229, -0.13588757812976837, -0.169096902012825, 0.029446322470903397, 0.07987992465496063, -0.07103652507066727, -0.07922766357660294, -0.199894979596138, -0.05662510171532631, 0.01925710402429104, -0.01679745875298977, -0.1236342266201973, -0.07438445836305618, 0.052543576806783676, 0.043578874319791794, -0.06381922215223312, 0.035580113530159, 0.03281467780470848, 0.07160423696041107, 0.0030344880651682615, 0.03520667180418968, -0.004099845886230469, 0.04814208671450615, -0.11163712292909622, 0.16482874751091003, 0.0077064926736056805, 0.1914251148700714, 0.1659471094608307, 0.004327773582190275, 0.21450930833816528, -0.08124379813671112, 0.08568323403596878, 0.026097411289811134, 0.1685541868209839, -0.04970722645521164, 0.02697083167731762, 0.013134387321770191, 0.05166403949260712, 0.05975356325507164, 0.0047880494967103004, -0.01616303063929081, 0.1618875414133072, -0.06853356957435608, 0.03768998384475708, 0.18164479732513428, 0.03562131151556969, -0.027191486209630966, -0.012538909912109375, 0.14420484006404877, -0.04254313185811043, -0.03710278496146202, -0.04066909849643707, -0.18344609439373016, 0.04484476149082184, 0.0480947308242321, -0.08671915531158447, -0.0992443636059761, -0.009678752161562443, -0.12249203771352768, 0.014935381710529327, 0.07276464253664017, -0.19376759231090546, 0.14506864547729492, -0.06511519104242325, -0.10372593253850937, -0.042620427906513214, 0.18031863868236542, 0.02371109277009964, -0.06896467506885529, 0.0067973569966852665, -0.1465749889612198, 0.0399802140891552, -0.09556780010461807, -0.022916683927178383, -0.04538862407207489, 0.14672382175922394, 0.062348540872335434, -0.062042009085416794, 1.2179911899351995e-32, -0.033319782465696335, 0.07162546366453171, 0.14037804305553436, 0.09720143675804138, -0.08298710733652115, 0.03139340132474899, 0.02686150185763836, 0.06630103290081024, -0.08501981198787689, -0.15566113591194153, -0.16926757991313934, 0.08216313272714615, -0.021275613456964493, 0.0881064310669899, -0.025051023811101913, -0.12743736803531647, -0.04421473294496536, -0.03316916897892952, -0.08593709766864777, -0.006640729494392872, 0.05627565085887909, 0.06681230664253235, 0.015160350129008293, 0.07034489512443542, -0.006376820616424084, -0.015844734385609627, -0.018675943836569786, 0.11310611665248871, -0.03143846616148949, -0.009516988880932331, -0.03484649956226349, 0.04315825551748276, -0.021821072325110435, -0.051067762076854706, -0.05774711072444916, -0.11899606883525848, -0.11239124834537506, -0.15641093254089355, -0.029223311692476273, 0.010685217566788197, 0.01925639994442463, 0.06855952739715576, -0.1793041229248047, -0.014796527102589607, 0.1586722880601883, -0.08577875047922134, -0.1186600998044014, -0.03926626220345497, -0.14633698761463165, 0.014423917979001999, 0.0026810583658516407, 0.13768097758293152, -0.06975292414426804, -0.07958844304084778, -0.12919633090496063, 0.04853445664048195, -0.011978201568126678, -0.06375516206026077, 0.0474698431789875, -0.02448861300945282, 0.0018144544446840882, -0.05521651729941368, 0.07339329272508621, -0.017632881179451942, -0.10628639906644821, 0.045744236558675766, 0.11005020886659622, 0.03799658268690109, -0.11286935210227966, 0.2617122232913971, 0.16062121093273163, -0.016746439039707184, -0.13739092648029327, -0.10234295576810837, 0.08290977030992508, -0.03662339970469475, 0.03961503133177757, 0.038103047758340836, 0.03977731242775917, -0.08167959749698639, -0.004788301885128021, 0.0018122113542631269, 0.055687908083200455, 0.16668464243412018, -0.037262964993715286, -0.08711406588554382, -0.03822829946875572, 0.007683838251978159, -0.06465325504541397, 0.016310079023241997, 0.06940266489982605, 0.0576602928340435, 0.05737221986055374, 0.14051543176174164, -0.019932275637984276, -1.2130770358015869e-32, 0.007976739667356014, -0.009151642210781574, -0.10020264983177185, 0.031160948798060417, -0.08239104598760605, 0.14742587506771088, 0.2319556623697281, -0.09685242176055908, 0.12332980334758759, -0.20425119996070862, -0.045440465211868286, -0.02440652623772621, 0.036559440195560455, -0.06043604016304016, -0.07505342364311218, 0.020039213821291924, 0.04958537593483925, 0.07450772076845169, -0.08229436725378036, -0.08164422959089279, -0.04501521214842796, 0.06626226007938385, -0.05364639684557915, 0.002992196474224329, 0.025871913880109787, 0.009741458110511303, 0.025439618155360222, 0.10300493985414505, 0.04091862961649895, -0.07610107958316803, -0.037503376603126526, 0.09978510439395905, -0.0030644696671515703, 0.09826932102441788, -0.06734281778335571, -0.041484810411930084, 0.10154296457767487, -0.17129017412662506, 0.011665397323668003, -0.07446254789829254, 0.039714522659778595, 0.12801750004291534, 0.0027071377262473106, 0.02679968811571598, 0.010423918254673481, 0.10044790804386139, 0.06504389643669128, -0.07198590785264969, 0.10721302032470703, 0.10965996235609055, 0.058962319046258926, 0.01871740259230137, -0.06374763697385788, 0.07270481437444687, -0.10843951255083084, 0.03350626677274704, -0.06785339117050171, -0.10005909204483032, -0.14477868378162384, 0.08281555771827698, -0.007603921461850405, 0.005525360349565744, -0.09531652927398682, -0.17081359028816223, 0.038490165024995804, 0.055148106068372726, 0.09776642173528671, 0.0124164754524827, 0.11878035962581635, -0.159763902425766, 0.08546315878629684, -0.11921870708465576, -0.11536835134029388, -0.12682843208312988, -0.14019593596458435, -0.030132897198200226, 0.03116527944803238, 0.019819924607872963, -0.007461619097739458, 0.06758139282464981, -0.011606771498918533, -0.09590094536542892, -0.03222327306866646, -0.04854706674814224, -0.008854798972606659, 0.00528061855584383, 0.0647202655673027, -0.11604263633489609, 0.0032105552963912487, 0.1593272089958191, -0.14704853296279907, -0.082892045378685, -0.10056322813034058, 0.04072292521595955, -0.06135296821594238, -1.0067897449062002e-07, 0.20613451302051544, -0.049705956131219864, -0.0001795809657778591, 0.04294750839471817, 0.15622369945049286, -0.04922117665410042, -0.06750763207674026, 0.08325708657503128, 0.035161565989255905, 0.20691271126270294, 0.16282619535923004, 0.08420229703187943, -0.05704538896679878, -0.046746205538511276, 0.09150031954050064, 0.037204474210739136, -0.20034854114055634, 0.03923385217785835, -0.07948186993598938, -0.03577132523059845, -0.009744266048073769, 0.10820958018302917, -0.06873015314340591, -0.018371256068348885, 0.06272519379854202, -0.0596936009824276, -0.00754431402310729, 0.038385163992643356, 0.08164133131504059, -0.12484881281852722, -0.18272121250629425, -0.087614044547081, 0.06947667896747589, -0.13642896711826324, -0.1591086983680725, -0.020482562482357025, 0.16413795948028564, 0.05599092319607735, 0.1192016452550888, 0.08749846369028091, 0.09514344483613968, -0.08034145832061768, 0.07382982224225998, -0.018683461472392082, -0.10710936039686203, -0.010650486685335636, -0.14046885073184967, -0.059574905782938004, 0.032641638070344925, -0.08633127808570862, -0.03374191373586655, -0.02869272418320179, 0.09443765878677368, -0.0013749991776421666, -0.15682578086853027, 0.11213336884975433, -0.18022571504116058, -0.0998319536447525, 0.10040192306041718, -0.05496812239289284, 0.005737612023949623, -0.23325616121292114, 0.12841573357582092, 0.14234307408332825], "changes": {"1wk": -20.355255816841055}}, {"text": "Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers Ramish Cheema Wed, Dec 11, 2024, 7:55 PM 8 min read In This Article: ARCT -6.89% We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers . In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street\u2019s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world. This relentless focus on change means that if the economy is facing turbulence, then markets are not kind to Wood. To understand how: consider the cumulative value of her firm\u2019s holdings as indicated by its 13F SEC filings. Starting from Q3 2020, analyzing the value for each subsequent year\u2019s third quarter reveals how Ark Invest\u2019s fortune fluctuates with economic winds. The hedge fund\u2019s holdings were valued at $16.8 billion, $41.6 billion, $14.3 billion, and $13 billion during Q3 2020, Q3 2021, Q3 2022, and Q3 2023, respectively. This shows that the value of Ark Invest\u2019s holdings jumped by 148% between the third quarters of 2020 and 2021. Looking back to see why, market conditions back then were marked by easy liquidity, a surge in retail investing, and Wall Street\u2019s bullishness for technology stocks. Technology and growth stocks are precisely the kinds that Wood invests in, and in the time period being analyzed, the shares of Elon Musk\u2019s car company alone soared by 87%. Wood is one of the firm\u2019s largest investors, and her patience has yielded results. Insider Monkey\u2019s data shows that Ark Invest first bought the shares at an average price of $13.14 during Q4 2016. While it has grown its holdings from the 274,725 shares held back then to 4.6 million shares as of Q3 2024, even if Wood hadn\u2019t bought additional shares, her original holdings would currently be worth $62.7 million right now for a remarkable 1,508% gain! Yet, while Musk\u2019s company is Wood\u2019s greatest hit, there have been misses as well since the idea of investing in disruptive innovation carries the unavoidable pitfall of targeting some firms that fail to deliver on lofty ideas. We analyzed the share price performance of some of her longest-held stocks as part of our coverage of 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood . At the time the list was published, its three worst-performing stocks were down by 81.85%, 95.11%, and 99% since 2020 end. Extrapolating their performance to December 2024, the first two stocks, which rank 2nd and 4th have lost 75% and 94.5%. Story Continues At the heart of Ark Invest\u2019s trading strategy is the fund\u2019s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index\u2019s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%. Wood\u2019s ETF\u2019s performance can also be divided into pre and post-election gains. Before the election, it was down 7.6% year-to-date after having bled 13% during H1 2024. As H1 ended, Wood acknowledged the troubling time her firm was facing in an investor letter. She admitted \u201cfully that the macro environment and some stock picks have challenged our recent performance\u201d but went on to add that her firm\u2019s \u201cconviction in and commitment to investing in disruptive innovation have not wavered.\u201d According to Wood, Ark had to remain persistent back then since exiting our strategies now would crystallize losses that lower interest rates and reversions to the mean should transform into meaningful profits during the next few years.\u201d The mean reversion she is referring to is the differential in the performance between the Russel Value and Growth stock indexes in the infamous dot-com bubble. Wood pointed out that \u201cAt its worst in 2000, the Russell Value Index underperformed the Russell Growth Index by more ~3,500 basis points on a year-over-year basis but, within roughly one year, the relative performance flipped and reached a positive ~4,800 basis points, more than an 80-percentage point swing, as shown below.\u201d She believes that Ark\u2019s strategy to diversify away from the Magnificent 6 (Magnificent 7 ex Tesla) through \u201cincreased exposure to multiomics stocks that have been hit hardest by \u201chigher for longer\u201d interest rates\u201d led to disappointing performance. The potential upside from this diversification was evident in 2023 as the flagship fund \u201cappreciated 68% as the bull market started to broaden out based on just the \u201cwhiff\u201d of lower interest rates, despite its diversification away from the Magnificent Six and toward what we believe are more disruptive names,\u201d according to Wood. To wit, while the flagship fund was down 7.6% YTD before the election after the ballots were cast and counted, it has gained 26% to bring its YTD performance to 20.46%. The benchmark S&P index, on the other hand, is up by 28.3%. Our Methodology For our list of the worst Ark stocks to buy according to short sellers, we ranked the 110 largest holdings in Ark Invest\u2019s Q3 2024 SEC filings by the percentage of shares outstanding that were sold short and selected the stocks with the highest percentage. For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Why Arcturus Therapeutics Holdings Inc. (ARCT) is the Worst ARK Stock To Buy According to Short Sellers? A pharmacist counting out doses of COVID-19 vaccine manufactured by the company. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Short Interest as % of\u00a0 Shares Outstanding: 16.56% Number of Hedge Fund Investors In Q3 2024: 17 Ark Invest\u2019s Q3 2024 Stake: $48.7 million Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is another biotechnology company in Cathie Wood\u2019s portfolio that does not generate revenue by selling medicines. The firm makes money from collaborations; however, it is developing drugs to treat high blood ammonia and cystic fibrosis. As Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a pre-revenue firm, the importance of its under-development drugs is paramount to its hypothesis. Two key drugs in its portfolio are ARCT-801 and ARCT-032 which target the aforementioned diseases. Both these treatments are in Phase 2 trials, and as of its third-quarter earnings update, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) plans to share their data in the first half of 2025. The firm is also developing a coronavirus treatment, and its Phase 3 data shows that the drug can protect against the virus and its variants for as long as six months post-vaccination. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)\u2019s management commented on its two key drugs during the Q3 2024 earnings call. Here is what they said: \u201cNow shifting our attention to our mRNA therapeutics franchise, let\u2019s begin with an update on ARCT-032. ARCT-032 is an inhaled messenger RNA therapeutic for cystic fibrosis, and it\u2019s formulated with Arcturus\u2019 lunar delivery technology that differentiates us from our competitors. In September, we received clearance of an investigational new drug application to the U.S. Food and Drug Administration. The FDA clearance of the IND application enables Arcturus to initiate a Phase 2 multiple ascending dose study to evaluate the safety, tolerability, and efficacy of ARCT-032 in people with cystic fibrosis. Overall, ARCT ranks 5th on our list of worst ARK stocks to buy according to short sellers. While we acknowledge the potential of ARCT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARCT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2024-12-11T16:55:08+00:00", "sentiment": {"score": 0.20050123520195484, "confidence": 0.2183012068271637, "probabilities": {"positive": 0.2183012068271637, "negative": 0.017799971625208855, "neutral": 0.7638987898826599}}, "embedding": [0.03243526071310043, -0.09308620542287827, 0.018297504633665085, 0.03842891752719879, 0.03673100471496582, -0.012905261479318142, 0.08791650831699371, 0.18516570329666138, 0.16280801594257355, 0.05497823283076286, -0.09049307554960251, 0.12072896957397461, -0.05081276223063469, -0.03644021973013878, -0.0950392484664917, -0.023329315707087517, -0.020728282630443573, -0.01979317143559456, -0.12517638504505157, 0.06578051298856735, -0.11983507126569748, -0.09860143065452576, -0.054314639419317245, 0.004567588679492474, 0.002223445102572441, 0.008826644159853458, -0.09935732185840607, -0.1058911681175232, -0.15623614192008972, -0.12951552867889404, -0.011605269275605679, 0.0965898185968399, -0.0015647932887077332, 0.044080570340156555, -0.12303613871335983, -0.019895993173122406, 0.006604310125112534, 0.035223327577114105, 0.09951908886432648, 0.015331937931478024, 0.0267304927110672, -0.012186858803033829, -0.04171023517847061, -0.0896175429224968, 0.008351515047252178, -0.08671338856220245, 0.046271324157714844, -0.05810188129544258, 0.029660135507583618, 0.027196098119020462, -0.10205540060997009, 0.001444417517632246, -0.053667161613702774, -0.12787070870399475, -0.08540493249893188, 0.07199302315711975, -0.022288167849183083, 0.0686325803399086, 0.11599244922399521, 0.07681019604206085, 0.1691770851612091, -0.051704041659832, 0.09339034557342529, -0.00998536217957735, 0.08834240585565567, -0.1142052412033081, 0.006179722025990486, 0.1616668850183487, -0.13140438497066498, 0.01982611045241356, 0.13818460702896118, 0.014335500076413155, -0.22338850796222687, -0.012902041897177696, -0.08588855713605881, 0.1429850161075592, 0.18721309304237366, 0.1140659898519516, 0.11330365389585495, -0.1538097858428955, 0.10355724394321442, 0.022975441068410873, -0.008922489359974861, -0.024343963712453842, -0.08264994621276855, 0.10905301570892334, 0.12093517929315567, 0.07903942465782166, 0.11810874193906784, -0.04548005014657974, 0.14882433414459229, -0.05650453269481659, -0.01782834902405739, -0.026196371763944626, 0.1055217981338501, 0.06559889018535614, -0.04698171094059944, -0.0017583295702934265, -0.10965891182422638, 0.0666307657957077, 0.10735026001930237, 0.09602172672748566, 0.06248915195465088, -0.06104341894388199, -0.06184697151184082, -0.13387657701969147, -0.006028043571859598, -0.03174188733100891, 0.01190976146608591, 0.0301415603607893, -0.0990389734506607, 0.04795391112565994, -0.09287811815738678, -0.005727929063141346, -0.011352615430951118, 0.0815659686923027, -0.14085891842842102, -0.07267438620328903, 0.06290801614522934, 0.045572880655527115, 0.11707693338394165, 0.03202022984623909, 0.019061926752328873, -0.006570015102624893, -0.12254586070775986, 0.008525836281478405, -0.08052675426006317, 1.0473447484947249e-32, -0.07058104872703552, 0.057100921869277954, -0.08976878225803375, -0.0952313244342804, -0.018390052020549774, 0.013171658851206303, 0.046999551355838776, -0.0698474645614624, -0.10328061878681183, -0.05568818747997284, -0.1301746964454651, 0.09216625988483429, -0.09257474541664124, -0.08762366324663162, -0.0514872670173645, -0.09949846565723419, -0.10185213387012482, -0.004228438250720501, 0.01987966150045395, -0.19160106778144836, 0.009200271219015121, 0.15029212832450867, -0.09170118719339371, -0.03104325570166111, 0.020152339711785316, -0.18000954389572144, -0.08189443498849869, -0.051580760627985, -0.07218567281961441, 0.07197748124599457, -1.1911033652722836e-05, 0.0018091564998030663, -0.050758879631757736, -0.06762772053480148, -0.008051058277487755, -0.07129108905792236, -0.039854712784290314, -0.10041414946317673, 0.11332470178604126, -0.044101789593696594, -0.07166614383459091, 0.1368168443441391, -0.05224589258432388, 0.015744151547551155, -0.05795081704854965, -0.002125984989106655, 0.046484097838401794, 0.07728281617164612, -0.08539178222417831, -0.011891579255461693, -0.12505875527858734, 0.07418224215507507, -0.010684818029403687, -0.04127806797623634, -0.05164951831102371, -0.03165585547685623, -0.07511986792087555, -0.168910950422287, -0.00013681640848517418, 0.0695011243224144, 0.06706850230693817, 0.1278497874736786, -0.042805880308151245, 0.0994035005569458, -0.3107090890407562, 0.23069368302822113, 0.06142871454358101, 0.06307373940944672, -0.034247927367687225, 0.11279795318841934, 0.05596597492694855, -0.10045736283063889, 0.07125914841890335, -0.08800722658634186, 0.016686659306287766, -0.08032108843326569, 0.00994933769106865, 0.10555528849363327, -0.013089661486446857, 0.050164323300123215, -0.013363322243094444, 0.02821565791964531, 0.08603579550981522, 0.06621062755584717, -0.03596261143684387, 0.03865090757608414, 0.03962831199169159, 0.029521742835640907, -0.02790028788149357, -0.021976571530103683, 0.08464524149894714, 0.0034665362909436226, 0.011387314647436142, 0.08811062574386597, 0.026722831651568413, -1.0050179152523006e-32, -0.11443378776311874, -0.05347612500190735, -0.013572290539741516, -0.0018876742105931044, -0.024789050221443176, -0.02349400892853737, 0.1156836524605751, -0.010089728981256485, -0.031138921156525612, -0.10978492349386215, 0.0026128236204385757, 0.04903972148895264, -0.029689500108361244, -0.0226410124450922, 0.006816769018769264, -0.08874572813510895, 0.10050573945045471, -0.11034110188484192, 0.07656605541706085, -0.05043535307049751, 0.08879375457763672, 0.04548802971839905, -0.07229998707771301, 0.20059996843338013, 0.01386610884219408, 0.051062505692243576, 0.02023180201649666, -0.11480042338371277, 0.014243662357330322, -0.06596328318119049, 0.03373049944639206, -0.006712751928716898, -0.10389001667499542, 0.16236624121665955, -0.06158033013343811, -0.026372335851192474, 0.05034244805574417, -0.11682967841625214, -0.12956878542900085, -0.08480937778949738, 0.16392073035240173, 0.07464642077684402, 0.07486067712306976, 0.019880712032318115, 0.07797444611787796, 0.06919795274734497, 0.05930701643228531, 0.05846831202507019, 0.26793384552001953, 0.0499674528837204, 0.03512008115649223, 0.0033413367345929146, 0.13194334506988525, 0.0598471574485302, -0.08751635253429413, 0.04138290882110596, 0.05516911670565605, 0.08169126510620117, -0.11890947818756104, 0.13002222776412964, -0.03223978728055954, 0.07705733925104141, 0.03040277399122715, -0.011683795601129532, -0.05454326793551445, -0.001104741357266903, -0.12158353626728058, -0.06517162919044495, -0.1321246474981308, -0.21570509672164917, 0.023781392723321915, -0.04958484694361687, -0.008875030092895031, -0.12098623067140579, -0.06407004594802856, 0.20896261930465698, 0.021346906200051308, -0.08770479261875153, -0.016941707581281662, 0.024197828024625778, -0.008116458542644978, 0.16126930713653564, 0.08942186832427979, 0.0010001808404922485, -0.06092637777328491, 0.11723288148641586, -0.07788430154323578, 0.008349736221134663, -0.03506962209939957, -0.014222336933016777, -0.09578967094421387, -0.26163801550865173, -0.0083922715857625, 0.012828376144170761, -0.019688334316015244, -1.0046096576843411e-07, 0.0005322499200701714, -0.06235518306493759, 0.05471095070242882, -0.009930652566254139, 0.03599521517753601, -0.08360441029071808, 0.09870623052120209, 0.09186285734176636, 0.04279525578022003, 0.15654098987579346, 0.03222937136888504, 0.07109691202640533, -0.20058849453926086, 0.15119974315166473, -0.10645252466201782, 0.11497194319963455, -0.09700402617454529, -0.014443635940551758, -0.0008054343052208424, -0.055867791175842285, 0.18079066276550293, 0.028520315885543823, 0.14796261489391327, -0.01381672453135252, 0.028806881979107857, 0.024864908307790756, -0.04538426175713539, -0.048134930431842804, 0.010885277763009071, 0.0943145602941513, 0.015746697783470154, -0.07897760719060898, 0.04487571865320206, 0.01577802374958992, 0.006261676549911499, 0.060259319841861725, 0.068751759827137, 0.1047225296497345, -0.04316598176956177, 0.10836368799209595, -0.06786750257015228, -0.007295997813344002, 0.049945853650569916, -0.05102797597646713, 0.012112102471292019, -0.06200020760297775, -0.11292697489261627, 0.022472336888313293, 0.07672654837369919, -0.22174066305160522, 0.11911442130804062, -0.04250425845384598, 0.06887252628803253, 0.019349751994013786, -0.02580251544713974, -0.025690343230962753, -0.10490693151950836, -0.018592454493045807, -0.15144488215446472, -0.05322684347629547, 0.07653582841157913, -0.25609302520751953, 0.10948153585195541, 0.19281330704689026], "changes": {"1wk": -17.437331114645993, "1mo": 0.16712411154216836}}, {"text": "Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates Zacks Equity Research Fri, Nov 8, 2024, 1:55 AM 3 min read In This Article: ARCT -6.89% Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 62.86%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $1.85 per share when it actually produced a loss of $0.64, delivering a surprise of 65.41%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Arcturus Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $41.67 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 15.23%. This compares to year-ago revenues of $45.14 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Arcturus Therapeutics shares have lost about 41.9% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for Arcturus Therapeutics? While Arcturus Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Arcturus Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.28 on $81.28 million in revenues for the coming quarter and -$2.60 on $218.29 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Bolt Biotherapeutics, Inc. (BOLT), has yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of +16.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Bolt Biotherapeutics, Inc.'s revenues are expected to be $1.02 million, down 59.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Arcturus Therapeutics Holdings Inc. (ARCT) : Free Stock Analysis Report Bolt Biotherapeutics, Inc. (BOLT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARCT", "date": "2024-11-07T22:55:08+00:00", "sentiment": {"score": -0.6510320752859116, "confidence": 0.7184762954711914, "probabilities": {"positive": 0.06744422018527985, "negative": 0.7184762954711914, "neutral": 0.21407946944236755}}, "embedding": [-0.08830585330724716, -0.06577332317829132, 0.0064006708562374115, 0.07865782082080841, -0.021850192919373512, -0.040133871138095856, -0.02978423982858658, 0.2756543457508087, 0.22694504261016846, 0.055589430034160614, -0.14685122668743134, 0.12114803493022919, 0.00012366333976387978, -0.023405762389302254, -0.12753672897815704, -0.012974904850125313, 0.086022287607193, 0.005084402859210968, -0.11597417294979095, 0.0062683578580617905, -0.054306890815496445, 0.001880561001598835, 0.10619096457958221, 0.09531660377979279, 0.09384381771087646, -0.0008201692253351212, -0.10642075538635254, -0.05388160049915314, -0.1959260106086731, -0.13921967148780823, -0.08633803576231003, 0.08998022228479385, 0.04678601399064064, -0.1291974037885666, -0.09199027717113495, -0.11062583327293396, -0.022419339045882225, 0.0453253909945488, 0.12922042608261108, 0.042125020176172256, -0.026644419878721237, 0.055896855890750885, -0.15285494923591614, 0.014994440600275993, -0.01844937726855278, -0.20912739634513855, -0.05672086030244827, -0.08040353655815125, 0.04351226985454559, 0.24677163362503052, -0.14292679727077484, -0.057809144258499146, 0.007412757724523544, 0.031229540705680847, -0.18827074766159058, 0.02261935919523239, -0.09692276269197464, -0.0033004572615027428, 0.07365873456001282, 0.08040189743041992, 0.10600191354751587, 0.029805902391672134, -0.024089397862553596, 0.05940882861614227, 0.1198960542678833, -0.03100968711078167, 0.06904894858598709, 0.06778687983751297, -0.051023587584495544, 0.024882465600967407, 0.14736971259117126, -0.030002787709236145, -0.14216361939907074, 0.10433587431907654, -0.11238756775856018, 0.11088971048593521, 0.17535129189491272, 0.15597115457057953, 0.04829347878694534, -0.06309497356414795, 0.13863447308540344, 0.03852948546409607, -0.030731873586773872, -0.015696000307798386, 0.06452736258506775, 0.04158264398574829, 0.18148963153362274, 0.22090737521648407, 0.105709969997406, 0.00035999203100800514, 0.02880651317536831, -0.044681817293167114, 0.006830248981714249, -0.05136023834347725, 0.059682123363018036, 0.02745988592505455, -0.07424452900886536, -0.11348940432071686, -0.037454575300216675, 0.09196449816226959, 0.08860985934734344, 0.060210295021533966, -0.03534936159849167, -0.09491641074419022, 0.0007680263370275497, -0.09933558851480484, 0.06886862218379974, -0.056091491132974625, 0.06113641709089279, 0.06900832802057266, -0.042600177228450775, 0.016573147848248482, -0.11021576076745987, 0.01021290011703968, -0.006604417227208614, 0.12420672923326492, -0.06440173834562302, 0.10688388347625732, 0.08299678564071655, 0.1537918746471405, 0.0987275242805481, 0.04649072140455246, 0.05168703943490982, -0.01549023948609829, -0.022286158055067062, 0.05451376736164093, -0.13050200045108795, 9.132439121425368e-33, 0.014219110831618309, 0.07833710312843323, -0.02793358638882637, -0.06051216274499893, -0.04065018147230148, -0.009623494930565357, 0.01832166500389576, -0.06360970437526703, -0.08667680621147156, -0.12830421328544617, -0.2100493311882019, 0.09017067402601242, -0.015016233548521996, -0.013758039101958275, -0.06928254663944244, -0.09489608556032181, 0.018084334209561348, 0.08748239278793335, -0.013018813915550709, -0.10058733820915222, -0.04365520179271698, 0.07637356966733932, -0.08625873178243637, 0.024245791137218475, -0.07785403728485107, 0.03289418667554855, -0.1267409771680832, 0.07257001101970673, -0.14380119740962982, 0.03518851473927498, -0.05324649065732956, -0.014331029728055, 0.11478665471076965, -0.1360398232936859, -0.051427654922008514, -0.03284193575382233, -0.022841503843665123, -0.10759327560663223, 0.2127237319946289, 0.032404784113168716, -0.07395067065954208, 0.1523934006690979, -0.141679048538208, -0.07431785762310028, -0.02820214442908764, -0.036297865211963654, -0.07327792048454285, 0.0200454443693161, -0.05748846381902695, -0.06526199728250504, -0.11494408547878265, 0.07581871747970581, 0.005206004716455936, -0.00854859035462141, -0.07164789736270905, 0.05734321475028992, -0.13263636827468872, -0.2069985568523407, 0.09270542860031128, 0.10614307224750519, 0.1498728096485138, 0.2176758497953415, 0.03502696752548218, -0.01070589292794466, -0.2856650948524475, 0.19946691393852234, -0.0037057376466691494, -0.010226411744952202, -0.07629320025444031, 0.19057469069957733, -0.07935413718223572, -0.05680522322654724, 0.06499451398849487, -0.04880676046013832, 0.23028478026390076, -0.1202693060040474, 0.03499497473239899, -0.006132298149168491, 0.02243010699748993, 0.0019911881536245346, -0.00872700847685337, -0.061278924345970154, -0.009737972170114517, 0.07328669726848602, 0.033156510442495346, 0.018262973055243492, -0.0019409018568694592, 0.0857953429222107, -0.051073819398880005, 0.00873237382620573, 0.08811160176992416, -0.0940333753824234, -0.07868839055299759, 0.15968909859657288, 0.04741319641470909, -8.068297881088537e-33, -0.10825134813785553, 0.09480676054954529, -0.05306314304471016, -0.05237463489174843, -0.07034129649400711, -0.0032436891924589872, 0.0627342015504837, 0.06705736368894577, 0.026190150529146194, -0.03450895845890045, 0.0497003011405468, 0.025196203961968422, -0.18214306235313416, 0.004577402025461197, -0.05826371908187866, 0.03293231874704361, 0.11679413914680481, -0.17114433646202087, 0.06542272865772247, -0.05194243788719177, 0.01963914930820465, 0.1943807452917099, -0.09006813913583755, 0.11082439869642258, 0.028071418404579163, 0.0732404887676239, 0.019566157832741737, 0.06905034184455872, 0.06730522960424423, -0.08176230639219284, -0.015483509749174118, -0.050534818321466446, -0.15113645792007446, 0.046591490507125854, -0.00558320851996541, 0.008965585380792618, 0.04067268595099449, -0.1300017535686493, -0.09898136556148529, -0.06930402666330338, 0.19232279062271118, 0.022611821070313454, 0.03388529643416405, -0.0040707457810640335, 0.12046268582344055, 0.019678134471178055, 0.08545629680156708, 0.03076709434390068, 0.20934508740901947, 0.08638355135917664, 0.01889621652662754, -0.0686916932463646, -0.03271222859621048, 0.14840441942214966, -0.07567354291677475, -0.03090984746813774, -0.02081380784511566, -0.005732425954192877, -0.17298416793346405, 0.029594527557492256, -0.0236704982817173, 0.10463527590036392, 0.024690303951501846, 0.004657448269426823, 0.011077549308538437, 0.10003531724214554, -0.0018071802332997322, 0.016590358689427376, -0.013760235160589218, -0.07606169581413269, 0.044294290244579315, -0.11771315336227417, 0.06310992687940598, -0.1271580308675766, 0.01339331828057766, 0.2291679084300995, -0.0616600476205349, -0.2143249809741974, -0.10104399919509888, -0.0371423065662384, 0.05488278344273567, 0.06455307453870773, 0.027185587212443352, -0.05433874577283859, -0.09217871725559235, 0.11758105456829071, -0.011074509471654892, 0.0032891584560275078, -0.042182907462120056, 0.0682026594877243, -0.028134480118751526, -0.2638598084449768, -0.08909402042627335, 0.013881989754736423, 0.14539799094200134, -1.0027335406448401e-07, 0.12962889671325684, 0.039595574140548706, 0.023175831884145737, 0.022375915199518204, 0.03582442179322243, -0.09978192299604416, 0.009155935607850552, 0.04940861463546753, 0.07339734584093094, 0.11870703101158142, 0.029088258743286133, 0.054601240903139114, -0.19719189405441284, 0.028997104614973068, -0.11048264056444168, 0.12361057847738266, -0.06937285512685776, 0.10842379927635193, -0.028910133987665176, -0.15908508002758026, -0.06145311892032623, 0.04864644259214401, 0.16609175503253937, -0.1702488660812378, 0.06055548042058945, -0.023627668619155884, -0.10028572380542755, -0.01918991655111313, -0.027747895568609238, -0.015814337879419327, 0.07526739686727524, -0.07481250166893005, 0.0060178195126354694, 0.04081512987613678, -0.035453036427497864, -0.1190372109413147, 0.037106871604919434, 0.06162363290786743, 0.07449575513601303, 0.056736208498477936, -0.07782654464244843, 0.017313458025455475, 0.02868160605430603, 0.06284554302692413, -0.01366087980568409, -0.06266676634550095, -0.027357004582881927, -0.048690315335989, 0.041353002190589905, -0.25346219539642334, 0.1416209191083908, -0.10667330026626587, 0.042794812470674515, -0.04884529113769531, 0.009568378329277039, 0.036618832498788834, -0.12656274437904358, -0.05219687893986702, -0.22334325313568115, -0.08931218087673187, 0.04977000132203102, -0.24765095114707947, 0.1507776379585266, 0.10028877854347229], "changes": {"1wk": -2.134469708728319, "1mo": 1.867664811870182}}]